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Cervical cancer is caused by infection with high-risk Human papillomaviruses (HPVs). 
It is ranked fourth among the top cancers in women worldwide, with ~87% of the global 
cervical cancer cases reported in developing countries. The HPV L1 capsid protein 
can self-assemble into virus-like particles (VLPs) that are structurally like native 
virions, which is the foundation on which commercially available vaccines have been 
developed. There are 3 commercially available HPV vaccines that are effective at 
preventing HPV infections, but are expensive, therefore limiting their use in the poorer 
developing countries where they are most needed. Thus, there is a need for more 
cost-effective HPV vaccines for use in these countries. Over the years, the use of 
plants to produce vaccines has begun to be more favourably looked upon as a cost-
effective alternative to conventionally used expression systems. The aim of this study 
was to evaluate the plant-based transient expression system as a tool to produce 
potentially cost-effective HPV L1 VLP-based vaccines, particularly for developing 
countries.  
Firstly, the L1 proteins of the 8 most common high-risk Human papillomavirus types in 
Africa (HPV 16, 18, 31, 33, 35, 45, 52, and 58) and 2 low risk types (HPV 6 and 34) 
were transiently expressed in Nicotiana benthamiana. The proteins were purified via 
isopycnic ultracentrifugation using sucrose and Optiprep™ density gradients, and the 
assembly of VLPs assessed by transmission electron microscopy (TEM). To further 
assess whether the VLPs are immunogenic, HPV 35, 52 and 58 were selected for 
mice studies. These were selected in particular, as HPV 35 is the fifth most prevalent 
type in Africa, and HPV 52 and 58 are among the most frequently reported high-risk 
types in Sub-Saharan Africa. VLPs representing the 3 HPV types were quantified and 
prepared for immunization in mice. The commercially available Gardasil® HPV VLP 
vaccine was used as a positive control. The immunogenicity of the vaccines was 
evaluated by testing for the presence of anti-L1 antibodies in sera from immunized 
mice using enzyme-linked immunosorbent assays (ELISAs) and western blots. Sera 
from immunized mice were also tested for the presence of neutralizing antibodies 
using pseudovirion based neutralization assays (PBNAs). 
L1 proteins of all 10 HPV types tested were successfully expressed in N. bethamiana, 
and TEM analysis showed that expression resulted in the successful formation of fully 
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assembled VLPs (40-60nm) as well as small VLPs and/or capsomeres (25-39nm). 
The analysis of the immune response showed that type-specific L1-specific antibodies 
were produced which were able to successfully neutralize homologous pseudovirions 
(PsVs) in PBNAs. Sera from mice immunized with plant-produced VLPs were further 
tested against heterologous HPV 6, 16, 18, 31, and 45 PsVs. However, none of the 
tested heterologous HPVs were neutralized, suggesting that plant-made VLPs 
induced type-specific neutralizing antibodies only.  
In conclusion, this study successfully demonstrated the potential for using plant-based 
transient expression systems to produce affordable and immunogenic HPV vaccines, 
particularly for developing countries. This is the first study describing the expression 
of 10 HPV L1 proteins in plants, marking a step towards the development of cheaper 
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1. Chapter 1: Literature Review 
 
1.1 Introduction  
Cervical cancer is ranked fourth among the top cancers in women and is the main 
cause of mortalities due to cancer among women of developing countries (Shrestha 
et al., 2018, Ferlay et al., 2015). In low- and middle-income regions, cervical cancer is 
ranked the second most common cancer with ~570 000 new cases reported in 2018, 
which attribute to 84% of worldwide cervical cancer cases. Approximately 311 000 
cervical cancer deaths were reported in 2018, with more than 85% deaths occurring 
in developing countries where screening and vaccination programmes are insufficient. 
This represents about 7.5% of all cancer deaths in females. In 2018, 62 170 prevalent 
cases (16.1% worldwide prevalence) were reported in Africa, with 8 593 cases 
reported in South Africa (Ferlay et al., 2018).  
Cervical cancer is caused by infection with high-risk HPVs (Ladd et al., 2019, Zur 
Hausen, 1996). Ninety nine percent of biopsy specimens from cervical cancers have 
been proven to contain HPVs, with HPV 16 being the most frequent, followed by HPV 
18 (Li et al., 2011). HPV 16 and HPV 18 are estimated to account for 70% of all cervical 
cancers worldwide, with other high-risk types (HPV 31, 33, 35, 45, 52 and 58) 
accounting for an additional 20% of cervical cancer worldwide (Ferlay et al., 2018).   
The causal linkage of HPVs to cervical cancer have attracted scientific attention. This 
has led to enhanced research in this field and as a result, three efficient prophylactic 
vaccines have been developed. Although cervical cancer deaths have been strongly 
reduced by using these HPV preventative vaccines, and screening for cervical cancer 
and timely treatment in industrialized countries, access to such services is a big 
challenge in developing countries (Denny, 2006, Moodley et al., 2006). Consequently, 
cervical cancer still remains a significant public health challenge in resource-poor 
countries (Franco and Harper, 2005). Therefore, there is still much to do to reduce 
HPV infections and cervical cancer deaths, especially in developing countries. This 
literature will review HPV as the main causative agent of cervical cancer, vaccines that 




1.2 The genome and classification of HPV 
1.2.1 The structure of HPV 
HPVs are small viruses that infect epithelial cells and have a 8 kb non-enveloped 
double-stranded circular deoxyribonucleic acid (DNA) genome (Mahdavi and Monk, 
2005, De Villiers et al., 2004). The genome has eight open-reading frames (ORFs) 
separated into three regions: the early (E) region which encodes the virus replication 
proteins (E1, E2, E4-E7); the late (L) region encoding the capsid proteins, the major 
L1 and the minor L2 structural proteins which are crucial for virion assembly; and the 
upper regulatory region (URR) which contains cis elements and is essential for viral 
replication and transcription (Figure 1.1) (Stanley, 2012).  
 
Figure 1.1| HPV genomic structure: The map of a typical high-risk HPV genome 
depicting the early genes E1, E2, E4-E7, the late genes encoding the L1 and L2 
structural proteins and the URR. AL is the late polyadenylation site while AE is the early 
polyadenylation site. Image modified with permission from  Stanley (2012). 
The HPV capsid is made up of two proteins: the L1 major capsid protein and L2 minor 
capsid protein (Pereira et al., 2009, Chen et al., 2000, Kirnbauer et al., 1993). The L1 
structural protein is approximately 56 kDa, while the L2 minor capsid protein is 
estimated at 64-78 kDa (Hagensee et al., 1994, Jin et al., 1989, Doorbar and 
Gallimore, 1987). The virion, measuring 50-60nm in diameter, contains 360 molecules 
of L1, arranged in 72 pentamers with an average of 30 L2 molecules (Buck et al., 
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2008, Trus et al., 2005) . Interaction among the 72 pentamers of L1 result in the T=7 
icosahedral symmetry of the virion (Figure 1.2) (Chen et al., 2000). 
                                                               T=7 
 
Figure 1.2| Atomic model of HPV 16 L1 capsid protein: The virion T=7 icosahedral 
symmetry. A 72-pentamer particle made up of full-length L1. Model obtained from 
http://viperdb.scripps.edu (Shepherd et al., 2006). 
1.2.2 Classification  
Traditionally, papillomaviruses and polyomaviruses belonged to one family, the 
Papovaviridae, as these two groups similarly have non-enveloped circular double 
stranded DNA genomes. Nevertheless, it was later found that papillomaviruses and 
polyomaviruses have different genome sizes and organizations, and do not share any 
resemblances in amino acid sequences, therefore, they are now recognized as two 
distinct families: Papillomaviridae and Polyomavidae, respectively (De Villiers et al., 
2004).  
Currently 16 genera are completely described in the Papillomaviridae family (Figure 
1.3). Among them, five genera known as Alpha-papillomavirus, Beta-papillomavirus, 
Gamma-papillomavirus, Mu-papillomavirus and Nu-papillomavirus  are found in 
humans and are denoted as HPVs (De Villiers et al., 2004). The Alpha genus group 
contains both the high risk and low-risk mucosal types which cause cervical cancer 
and genital warts, respectively, whereas other genera consist of cutaneous HPV types 
(Doorbar et al., 2012). 
Scientists have been using the highly conserved gene of the papillomaviruses, the L1 
ORF in the identification of new papillomavirus types (De Villiers et al., 2004). 
4 
 
Presently, more than 118 HPV types have been identified and described according to 
their oncogenic potential and biological niche (Zandi et al., 2010, De Villiers et al., 
2004). Moreover, based on the molecular and epidemiological evidence, HPV types 
are divided into low-risk (mostly found in genital warts and are known to cause benign 
lesions) and high-risk types (known to cause malignant lesions and mainly linked with 
invasive cervical cancer) (Muñoz et al., 2003). Among the low risk HPV types are HPV 
6, 34 and 11, and the high risk types include HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 
56, 58, and 59 (Zandi et al., 2010).  
 
Figure 1.3| Taxonomic classification of papillomaviruses: Phylogenetic tree of 
genera and species of papillomavirus based on the ORF sequences of L1. Tree 
obtained with permission  from de Villiers (2013). 
1.3 HPV life cycle 
1.3.1 Viral Entry 
HPVs are intracellular parasites, therefore they must be able to insert their genomes 
into the host target cells to recruit cellular machinery for replication (Marsh and 
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Helenius, 2006). HPV virus particles enter the basal keratinocytes of the infected 
epithelium, with the viral structural proteins playing essential roles during viral infection 
(Roberts et al., 2007). The development of organotypic raft cultures and later VLPs 
and PsVs have allowed researchers to produce infectious virus particles and therefore 
study the HPV life cycle in vitro. 
Initial contact between the virus and the host cell during in vivo infection is initiated by 
binding of the virus to the basement membrane (Figure 1.4) (Kines et al., 2009, Day 
et al., 2008, Richards et al., 2006). Figure 1.4 shows a series of steps involved during 
viral infection. The initial interaction between the virus and the basement membrane 
causes conformational changes in the virion which is essential for viral infection (Kines 
et al., 2009). Conformational changes in the virion  exposes L2 cross-neutralization 
epitopes to furin and/or proprotein convertase (PC) 5/6 cleavage and enables transfer 
of the virus to cell receptors (Kines et al., 2009). 
 
Figure 1.4| Schematic model of initial steps during natural infection: The 
attachment of virion on the basement membrane exposes L2 to furin cleavage and 
ultimately transfer to cell receptors. Image adapted  with permission from Kines et al. 
(2009). 
In contrast to natural infection, the initial contact between the HPV capsid and the host 
cell in in vitro is initiated by binding of the HPV capsid on the cell surface receptors 
(Kines et al., 2009, Roberts et al., 2007, Giroglou et al., 2001a, Joyce et al., 1999). 
Particularly, during  in vitro infection , the initial interaction depends on the attachment 
of the major L1 capsid protein on the cell surface heparan sulfate proteoglycans 
(HSPG) (Kines et al., 2009, Drobni et al., 2003, Giroglou et al., 2001b). Notably, in 
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vitro HPV can also bind to a receptor found in the extra-cellular matrix (ECM) known 
as laminin-5. However, the interaction with laminin-5 is not as important for efficient 
HPV infection as the HSPG interaction (Culp et al., 2006a, Culp et al., 2006b).  
The L1 interaction with HSPG causes conformational changes to the viral capsid 
before cell entry. Specifically, the surface binding exposes the L2 N-terminus to furin 
cleavage (Day et al., 2008, Richards et al., 2006). Furin cleavage of L2 occurs at a 
furin consensus site which is preserved in all papillomaviruses (Richards et al., 2006). 
This binding causes another conformational change and exposes the secondary cell 
receptor binding sites to the L2 molecules (Day et al., 2008, Day et al., 2007). The 
main difference between in vivo and in vitro infection is the conformational change of 
L2 molecule that occur on the basement membrane, and after cell surface adsorption 
respectively (Day et al., 2008).  
After HPV virions successfully attach to the cell surface receptors, they are 
translocated into the cell to begin the infection. Currently, the entry mechanisms 
associated with HPV interaction with the target cell are still a topic of scientific 
discussion (reviewed in Horvath et al. (2010)). Non-enveloped viruses are known to 
use either caveolae or clathrin mediated endocytic pathways to successfully infect 
cells (Smith and Helenius, 2004). Studies suggest that efficient cell entry of HPV 
virions comprises translocation by endocytosis. Studies that investigated HPV 16 entry 
reported the association of clathrin-dependent endocytosis (Spoden et al., 2008, 
Bousarghin et al., 2003, Day et al., 2003), while caveolar-mediated mechanisms were 
observed in HPV 31 (Smith et al., 2007b, Bousarghin et al., 2003). 
1.3.2 HPV as an infectious agent 
HPVs are infectious agents which are categorized by their tissue tropism and species 
specificity (Stanley, 2006). The HPV infectious cycle entirely depends on the host 
keratinocyte cell replication and differentiation activities of the target cell (Stanley, 
2012). This has hindered the study of the virus’s infectious cycle until the development 
of the organotypic raft culture system. This system allowed the establishment of an in 
vitro system which mimics in vivo epithelial features and is able to reproduce the 
complete life cycle of HPV (Kreider et al., 1987). This system allows HPV genomic 
DNA to be introduced into keratinocytes and isolate cells that are like undifferentiated 
basal cells. HPV cell lines used in this system are obtained either from infected 
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epithelial tissues or produced by introducing HPV genomic DNA into keratinocytes 
(McLaughlin-Drubin and Meyers, 2005). 
HPV requires epithelial micro-abrasions for viral entry to the basal epithelial cells 
(Doorbar et al., 2012, Conway and Meyers, 2009). The life cycle of HPV is separated 
into the non-productive phase and the productive phase (Figure 1.5) (Stanley, 2006).  
 
Figure 1.5| Infectious HPV life cycle: The virus gains entry to the basal cells of the 
epithelial via micro-abrasions. The non-productive stage of the life cycle happens in 
the proliferative compartment of the epithelium. Viral gene expression and DNA 
amplification of thousands of genome copies occurs in the productive stage of the life 
cycle. Late virus proteins such as L1, L2, and E4 are synthesized, and eventually 
virions are assembled. Image taken with permission from  Stanley (2006). 
The non-productive phase, also known as the phase of plasmid maintenance, occurs 
immediately after the virus enters the basal layer of epithelial cells. The virus 
synthesizes its DNA once per cycle of host replication, hence the genome is sustained 
as a low copy number episome (Doorbar et al., 2012). The early E1 and E2 proteins 
of the virus are expressed during this phase. These proteins are necessary for viral 
DNA replication, because together they form a complex that has the origin of 
replication and recruit the host cell replication machinery (Conway and Meyers, 2009). 
During this phase, the virus gene expression is highly controlled, thus the E6 and E7 
oncogenes are poorly expressed (Stanley, 2012).  
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The viral productive phase happens in the surprabasal layers of epithelial cells. Here 
the virus amplifies its DNA using the host replication tools to yield many viral genomes. 
Late proteins, such as L1, L2 and E4, are expressed in this phase and eventually lead 
to viral packaging and assembly (Stanley, 2006, Heino et al., 2000). In this phase all 
viral genes are expressed and leave the cell as infectious viral particles (Stanley, 
2012). Keratin cells collapse after the  E1-E4 proteins interconnect their networks, 
therefore, letting mature virions escape (Conway and Meyers, 2009). It takes 
approximately 3 weeks for these infectious virus particles to be synthesized (Stanley, 
2012).   
Normally, after cell division of basal cells, daughter cells disconnect from the basement 
membrane, and move to the suprabasal compartments to initiate differentiation  
(Fehrmann and Laimins, 2003). In contrast, HPV infected suprabasal cells do not 
leave the cell cycle, but remain to support HPV DNA synthesis and eventually HPV 
virions (Doorbar et al., 1997).   
1.3.3 Virion assembly and maturation  
An effective virus is one that is able to produce new viral components (transcription 
and translation) inside the host cell and assemble them to mature into stable virions 
which can effectively infect other hosts. Most viruses use chaperones or scaffolding 
proteins to successfully accomplish the task of assembly (Villarreal, 2004). 
Failure to grow efficient amount of the virus in cultures has greatly affected the studies 
of capsid assembly of the HPV virion. This is because viral DNA replication and 
transcription are tightly dependent on the host target cell differentiation activities (Chen 
et al., 2000). Molecular interactions required for HPV assembly are not well 
understood (Conway and Meyers, 2009). Furthermore, the role of the minor L2 
structural protein in HPV assembly is not well understood (Buck et al., 2005b).  
It is reported in literature that the viral genome can be packaged into VLPs made of 
both the L1 and L2 proteins, however not into L1 composed capsids (Heino et al., 
2000). This partly suggests that the L2 minor capsid protein is essential for HPV virion 
assembly, specifically the viral genome encapsidation (Holmgren et al., 2005, Heino 
et al., 2000). Although it is still unknown how this capsid protein facilitates 
encapsidation of DNA, it is hypothesized that L2 binds to E2 and uses it to traffic the 
genome of the virus to where virion assembly occurs (Holmgren et al., 2005).  
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HPV genome replication occurs in the nuclear substructures known as nuclear domain 
10 (ND10) (Tavalai and Stamminger, 2008). In natural infection this site serves as the 
localisation site of expressed L2, which is essential for capsid assembly. Florin et al. 
(2002) worked on the translocation of the structural L1 and L2 proteins of HPV 33 and 
noted that they are independently translocated into the nucleus where virion assembly 
happens. This is because both the L1 and L2 proteins have nuclear localization 
sequences which enable their translocation (Darshan et al., 2004). In vivo, 
translocation of L2 from the cytoplasm precedes that of L1 (Florin et al., 2002). The 
authors also showed that L2 expression and localization in ND10 precedes L1 
accumulation by several hours. Interestingly, Egawa et al. (2000) showed that HPV 1 
L1 is expressed and located in the nucleus all over the epithelium, whereas L2 was 
only expressed in the upper epidermal layers  
Conway et al. (2009) demonstrated that, following capsid assembly, naive virions 
utilize natural redox gradients in the upper layers of differentiating epithelial cells to 
facilitate redox-dependent maturation by forming disulfide bonds among neighbouring 
L1 proteins. Using cell culture derived capsids Buck et al. (2005b) showed that 
papillomavirus capsid maturation is a very slow process that is associated with 
disulphide bond formation among molecules of L1 protein. Capsid maturation results 
in more stable capsids that are resistant to proteolytic lysis (Buck et al., 2005b). 
Interestingly, contrary to the conventional lytic cycle of non-enveloped viruses, it is 
suggested that papillomaviruses are released by desquamation, a process where 
keratinocytes lose their structural stability after they are freed from the skin surface 
(Cardone et al., 2014, Buck et al., 2005b). The authors suggested that, capsids are 
stabilized through disulfide interactions in the oxidative environment before their 
release into the environment. 
1.4  Native and Synthetic HPV Particles 
Virions from organotypic cultures are not yet structurally comparable to those from 
natural infection, however, their production depends on the differentiation of 
keratinocytes, which indicates their novelty (Conway and Meyers, 2009). These 
systems however are time consuming and inefficient in the production of native HPV 
virions (Conway et al., 2011). The production of synthetic particles (VLPs and PsVs) 
partially overcame these restrictions (Horvath et al., 2010). This involves the 
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expression of HPV structural proteins and a reporter gene (in the case of PsVs) in 
eukaryotic expression systems. The structural and immunological features of these 
particles are similar to those of the parental HPV virions (Xu et al., 2006). 
1.4.1 Virus-like particles 
The capsid proteins of many viruses self-assemble into VLPs with similar structural 
properties as native viruses (Grgacic and Anderson, 2006). Figure 1.6 illustrates the 
main difference between HPV L1 VLP and authentic virion. Although VLPs mimic 
native virions, they are not infectious since they do not contain the genetic material of 
the virus (Figure 1.6) (Deml et al., 2004). Furthermore, these VLPs display high 
densities of epitopes which often stimulate strong immune responses (Grgacic and 
Anderson, 2006). This makes them effective vaccine candidates for many viruses. In 
addition to the absence of the viral genome, VLPs ensure tissue-specificity making 
them safe vaccine candidates contrary to attenuated or inactivated virus vaccines 
(Chroboczek et al., 2014). Notably, VLPs can trigger cytotoxic T lymphocyte and 
cluster of differentiation-4 (CD-4) proliferative responses (Paliard et al., 2000). 
 
Figure 1.6| Schematic composition of HPV L1 VLP versus native virion: VLPs are 
structurally like native virion, except that they lack the viral genome. Image adopted 
from Yu (2017). 
HPV VLPs are produced by expressing the major L1 structural protein on its own or 
together with the minor L2 structural protein. VLPs for vaccine candidates must be 
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produced in expression systems that are safe, yet yield high production (Noad and 
Roy, 2003). Traditionally, the inability to propagate HPV in vitro as well as the  absence 
of efficient expression systems hindered the development of HPV vaccines (Mach et 
al., 2006). However, in recent years several methods have been described for 
successful production of HPV VLPs. The first method produced HPV virions by 
transfecting mammalian cells with vaccinia viral vector (Zhou et al., 1991). Other 
methods used insect-cells (Paavonen et al., 2007), yeast (Mach et al., 2006) and 
bacteria (Chen et al., 2000). Interestingly, HPV VLPs have also been produced in 
plants (Chabeda et al., 2019, Fernández‐San Millán et al., 2008, Maclean et al., 2007, 
Biemelt et al., 2003). Notably, these particles resemble native virions structurally and 
immunologically (Biemelt et al., 2003). 
Antibodies induced by canine oral papillomavirus (COPV) VLPs protected beagles 
against experimental oral mucosal papillomas infections (Suzich et al., 1995). 
Furthermore, cottontail rabbit papillomavirus (CRPV) VLPs  protected rabbits against 
experimentally induced CRPV (Breitburd et al., 1995). Interestingly, HPV VLPs 
activated dendritic cells in vitro, which activates primary immune response against 
pathogens in vivo (Lenz et al., 2001, Rudolf et al., 2001). Most studies demonstrated 
that, vaccinations with HPV VLPs result in high titres of protective antibodies, thus 
protecting humans from HPV infections (Ault et al., 2004, Fife et al., 2004, Emeny et 
al., 2002, Koutsky et al., 2002). VLPs have since been applied as prophylactic 
vaccines against HPV, they are the foundation on which the current commercially 
available HPV vaccines have been developed. 
1.4.2 Pseudovirions  
After the production of HPV VLPs that resemble parental virions, some groups showed 
that viral L1 and L2 capsids can encapsidate reporter plasmids to generate PsVs that 
infect cells and tissues (Buck et al., 2005a, Roden et al., 1996). Roden et al. (1996) 
used a Semliki Forest virus vectorto generate PsVs for HPV 16 in hamster BPHE-1 
cells, whereas Unckell et al. (1997) used the vaccinia viral vector to generate PsVs for 
HPV 33 in monkey COS-1 cells. The authors noted that the minor L2 structural protein 
is essential for genome encapsidation.  
PsVs can efficiently deliver plasmid DNA into multiple cell lines and tissues, in a similar 
way to a native HPV virion delivering it’s genome, thus they can be used to measure 
12 
 
protective neutralizing antibody titers in vitro or in vivo and in medical applications such 
as gene therapy (Ma et al., 2011). Interestingly, Hung et al. (2012) showed that HPV 
16 PsVs can successfully deliver herpes simplex virus thymidine kinase (HSV-tk) 
gene to ovarian tumour cells, resulting in significant therapeutic anti-tumor effects 
in mice. This suggest that HPV PsVs can be utilised as a potential gene delivery 
system in gene therapy. 
Apart from failure to propagate HPV in tissue culture, the absence of effective 
neutralizing assays has been a major drawback in the production of vaccines against 
HPV infections. The development of PsVs has enabled researchers to measure 
neutralization of HPV infectivity both in vivo and in vitro. Subsequently, PsVs are 
used in PBNAs (Buck et al., 2005a, Pastrana et al., 2004, Yeager et al., 2000). 
PBNAs are considered as  standard assessment for the immunogenicity of HPV 
candidate vaccines (Lamprecht et al., 2016). However, PsVs are currently made in 
human embryonic kidney cells (HEK293TT cells) which is a highly expensive 
system. This might be a major drawback in the development of affordable HPV 
vaccines for developing country and a cost-effective alternative would be good. In 
an attempt to reduce the high expenditure associated with PsVs production in 
mammalian cells, Lamprecht et al. (2016) successfully produced PsVs in plants with 
comparable characteristics to mammalian produced PsVs.  
In in vitro standard assays, HPV L2 based vaccines yield very low level of neutralising 
antibodies (Day et al., 2012), although they effectively protect animals against 
experimental challenges (Gambhira et al., 2007a, Palmer et al., 2006, Embers et al., 
2002). Therefore, there is a possibility that standard neutralization assays are not a 
sensitive measurement for HPV L2 based vaccines infectivity, this led to the 
development of L2-specific PBNA. This assay development was based on the 
understanding of initial steps that happen on the basement membrane during viral 
infection, particularly the conformational change that expose cross-neutralization 
epitopes of L2 molecule (Day et al., 2012).   
1.5 Detection of HPV infections 
Cervical cancer deaths have been reduced in developed countries due to timely 
screening and intervention. Screening  of cervical cancer has essentially been based 
on the cost-effective cytology-based method described by George Papanicolaou  
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known as the Papanicolaou test, or “Pap smear” (Papanicolaou and Traut, 1941). The 
method detects early cervical lesions, and have successfully reduced the cervical 
cancer mortality rate, especially in developed countries (Behtash and Mehrdad, 2006, 
Levi et al., 2000).  
However, false-negative results have been reported in Pap smears as the efficacy of 
the test largely depends on the sample quality (Cuzick et al., 2006, O'Meara, 2002). 
Since then, research have focused on the development of screening technologies that 
will complement and improve the cytology-based methods. Subsequently, novel 
diagnostic tools for detecting HPV infections have been established, these include: 
detection of carcinogenic HPV DNA with polymerase chain reaction (PCR)-based 
methods, the use of epithelial cell markers to detect HPV early and/or late proteins, 
and finally serological markers to detect HPV antibodies in serum and other body fluids 
(Pagliusi and Garland, 2007).  
PCR-based screening of cervical cancer by targeting HPV DNA have demonstrated 
high sensitivity for cervical intraepithelial neoplasia (CIN) than that achieved by 
cytology-based method (Cuzick et al., 2006). However, factors such as age at which 
to begin cervical screening may negatively influence reduction of cervical cancer using 
HPV DNA testing methods (Ylitalo et al., 2000, Cuzick et al., 2006). On the other hand, 
the immunological detection of HPV in human cells and tissues is being hindered by 
3 main factors. These are: low expression level of HPV early proteins, expression of 
the E6 and E7 proteins only in the productive phase, and lack of quality antibodies 
with high sensitivity against the viral proteins (Pagliusi and Garland, 2007). 
Serological assays for screening HPV antibodies in sera and other body fluids have 
been described, although the diagnostic value for HPV detection in other body fluids 
is yet to be established. Monoclonal antibodies that can identify and characterize 
different HPV neutralizing epitopes have been developed (Christensen et al., 1996b). 
However, these antibodies are not commercially available and currently made in mice 
and are costly. Costly production of these antibodies may potentially restrict their use 
in developing countries. Therefore, there is a need to develop HPV antibodies using 
an affordable system that can be used in diagnostics and research. 
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1.6  HPV vaccines 
1.6.1 Prophylactic HPV vaccine 
1.6.1.1  Licensed HPV prophylactic vaccines 
Generally, vaccination is the most cost effective and successful intervention in 
preventing infectious diseases (Kushnir et al., 2012, Daniell et al., 2009). Traditionally, 
viral vaccines were either attenuated or inactivated virions. These vaccines have been 
historically effective, such that they have led to the eradication of target pathogens, for 
example smallpox in humans. However, live attenuated vaccines can cause side 
effects especially in immune-compromised individuals (reviewed in Plotkin (2005)). 
This led to the establishment of other alternative approaches, to develop effective yet 
safe vaccines. 
A major advance in recombinant DNA technology and genetic engineering was the 
establishment of sub-unit vaccines in 1988 (Murray, 1988). Specifically the usage of 
VLPs to produce safe sub-unit vaccines with enhanced immunogenicity (Kushnir et 
al., 2012). Currently, there are vaccines in the market that are VLP-based like Sci-B-
Vac™ for Hepatitis B virus (HBV); and Gardasil®, Cervarix™ and Gardasil9® for HPV. 
Currently, plant-made VLP-base vaccine against Avian H5N1 Influenza by Medicago 
Inc is phase III of human clinical trials (Pillet et al., 2019).  Furthermore, Mosquirix™ 
developed by GlaxoSmithKline for malaria was  approved by European regulators 
(Hawkes, 2015). 
Just like any other infection, the recognition of HPV infection as the etiological agent 
of cervical cancer motivated researchers to focus on the production of HPV vaccines. 
The major L1 structural protein has the potential to self-assemble into VLPs that are 
structurally and immunogenically like native virions (Mach et al., 2006), which is the 
foundation on which current commercially available HPV vaccines have been 
developed. 
Currently, there are 3 commercially available prophylactic VLP-based HPV vaccines 
which elicit neutralizing antibodies. These vaccines are all formulated in aluminum-
based adjuvants and are generally known to be highly effective and safe (Joura et al., 
2015, Clark et al., 2013, Mesher et al., 2013). In 2006, the United States of America 
(USA) Food and Drug Administration (FDA) approved the first HPV vaccine for use in 
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humans: Gardasil® a quadrivalent HPV 11/18/6/16 L1 VLP vaccine by Merck and Co. 
Inc, which protects against  HPV 6, 11, 16 and 18. Additionally, in 2009 the FDA 
approved a second vaccine, the bivalent HPV 18/16 VLP vaccine, Cervarix™ 
developed by GlaxoSmithKline. This vaccine protects against HPV 16 and 18 
infections. 
Both Gardasil® and Cervarix™ are efficacious against their corresponding HPV types 
(Paavonen et al., 2009, Garland et al., 2007, Harper et al., 2006). Interestingly, there 
is cross-protection of HPV 31, 33 and 45 with CervarixTM, and HPV 31 with Gardasil® 
(Paavonen et al., 2009, Wheeler et al., 2009, Harper et al., 2006). However, the 
authors noted that the strength of the cross-neutralizing antibodies are lower than 
those of the targeted HPV types.  
In 2014 the FDA approved yet another vaccine, Gardasil9®, a nonavalent HPV 
6/11/16/18/31/33/45/52/58 vaccine. Gardasil9® has a high L1 antigen load, and has 
the potential to prevent 90% of anal, vulvar, vaginal and cervical cancers (Printz, 
2015). However, the worldwide distribution and occurrence of HPV types differ per 
geographic regions with Africa having the highest occurrence of ~21.1-29% of HPV 
infections (Zhai and Tumban, 2016). Therefore, the vaccine might have different 
success rates in different regions. For example, in Africa where the highest burden of 
cervical cancer is reported, HPV 35 is more prevalent and important than other HPV 
types included in the current vaccines (Smith et al., 2007c). Unfortunately, HPV 35 in 
not included in any of the commercially available vaccines.   
The government of some countries such as Australia and the USA have introduced 
national HPV vaccine programmes with Gardasil9®. In fact, by 2017 and 2018 
Gardasil9® was the only HPV vaccine available for distribution in the USA and 
Australia, respectively (Markowitz et al., 2018). Gardasil9® is well tolerated, highly 
immunogenic and efficacious against high-grade cervical and cytological 
abnormalities caused by HPV types included in the vaccines (Garland et al., 2018, 
Ruiz-Sternberg et al., 2018, Huh et al., 2017).  
Although these vaccines are effective at preventing HPV infection, they are type-
restricted, meaning they offer protection to a restricted number of HPV types (Matić et 
al., 2012). Therefore, second-generation HPV preventative vaccines that will produce 
a wider spectrum protection against multiple HPV oncogenic types need to be 
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developed. Furthermore, these vaccines are produced in highly expensive expression 
systems. Gardasil® and Gardasil9®, are produced in the Saccharomyces 
cerevisiae yeast expression system, whereas Cervarix™ is produced in insect-cells 
(Hi-5-Rix4446 derived from Trichoplusia ni) (Palmer et al., 2009). 
Due to high cost associated with the commercially available HPV vaccines, most low-
income countries are not yet ready to introduce HPV vaccination programmes, with 
only 7 out of 54 African countries having vaccination programmes as of May 2018 
including South Africa (Chido-Amajuoyi et al., 2019). Only CervarixTM and Gardasil® 
are currently available for distribution in Africa, which only protect against few 
oncogenic HPV types. In South Africa Gardasil® is available in private sectors, 
whereas CervarixTM is currently administered to girls aged ≥ 9 years, which is part of 
the national HPV vaccine programme that was introduced in 2014 (Delany-Moretlwe 
et al., 2018). Consequently, there is a need to develop affordable multivalent HPV 
vaccines for use especially in developing countries, where cancer of the cervix is the 
greatest burden with a reported 87% of the global HPV infection (Ferlay et al., 2015). 
1.6.1.2 Second generation prophylactic vaccines 
1.6.1.2.1 L2-based vaccines 
L1 is known to be more immunodominant than L2 (Palmer et al., 2009). As a result, 
several groups successfully produced HPV L1 VLPs (Chabeda et al., 2019, Maclean 
et al., 2007, M’hirsi El Adab et al., 2007, Warzecha et al., 2003, Kirnbauer et al., 1992). 
Research based on highly immunogenic HPV L1 VLPs led to FDA approval and 
commercial sales of VLP-based vaccines. However, the unaffordability and the type-
specificity of these vaccines and their poor cross protection of heterologous HPV types 
are the major drawback of these vaccines.  
In an effort to overcome these challenges, specifically the poor cross-protection 
against heterologous HPV types, early efforts discovered that the amino terminus of 
the minor L2 structural protein comprises epitopes capable of inducing protective 
neutralizing antibodies against HPV (Campo et al., 1997, Knowles et al., 1997, 
Chandrachud et al., 1995). Regardless of this discovery, recombinant L2 
demonstrated poor immunogenicity compared to L1 VLPs.  
17 
 
Few groups demonstrated that the HPV L2 amino terminus can trigger neutralizing 
antibodies that can defend against specific HPV types and cross-neutralize other 
HPVs (Slupetzky et al., 2007, Palmer et al., 2006, Pastrana et al., 2005, Roden et al., 
2000) . This directed researchers to focus on HPV L2-based vaccines as alternatives 
to types-specific L1 based vaccine candidates. Particularly to locate L2 sequences 
that can cross-neutralize other papillomavirus infections (Alphs et al., 2008, Gambhira 
et al., 2007b). 
In vivo immunogenicity of a distinct region of L2 was demonstrated using rabbits 
(Embers et al., 2002). This group immunized rabbits with synthetic peptides each 
containing short peptides of L2 from either CRPV or rabbit oral papillomavirus (ROPV) 
and subsequently challenged rabbits with CRPV and ROPV. Both oral and cutaneous 
papilloma growths were inhibited in rabbits immunized with the ROPV and CRPV 
peptides, respectively. 
Roden et al. (2000) demonstrated cross neutralization of heterologous HPV types by 
L2 polypeptides of HPV 18, 6 and 16. Additionally, Palmer et al. (2006) used 
recombinant tobacco mosaic virus (TMV), comprising CRPV L2 epitopes to 
successfully protect rabbits from experimentally induced papillomavirus with cross-
protective immunity. Slupetzky et al. (2007) further demonstrated the cross-protection 
ability of HPV 16 L2 epitopes against HPV 11. From all these data it is evident that L2 
epitopes might be a good target for the development of broad-spectrum protection. L2 
induced neutralizing antibody titres are however usually 2-3 orders of magnitude less 
than L1-induced titres (Pastrana et al., 2005).  
1.6.2 Therapeutic HPV vaccines. 
Commercially available prophylactic vaccines are effective at preventing HPV 
infections, however there is a high occurrence of established HPV infections globally 
which current vaccines are ineffective at treating (Kim et al., 2014, Lin et al., 2010, 
Schiller et al., 2008). Current vaccines are designed to induce neutralizing antibodies 
by targeting HPV structural proteins (L1 and L2). However, these capsid proteins are 
not detectable in HPV infected cells after primary infections (Schiller et al., 2008). 
Epithelial cells infected with HPV present non-capsid proteins in the context of major 
histocompatibility complex (MHC) class I to the immune system (Frazer, 2009). 
Therefore, to effectively treat existing infections and associated lesions, therapeutic 
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HPV vaccines are required to induce antigen-specific cellular immune responses 
against cells infected with HPV (Lin et al., 2010, Frazer, 2009). 
To date, HPV therapeutic vaccines are designed to use the early genes E6 and E7 as 
antigens because they are tumour-specific, and are not self-protein hence there are 
no concerns of autoimmunity (Lin et al., 2010, Hung et al., 2008a). Furthermore, they 
are involved in cell disruption and are expressed constitutively in cervical cancers and 
premalignant lesions (Zur Hausen, 2002). Currently, there is no approved therapeutic 
HPV vaccine. However, several approaches have been studied with the hope of 
developing effective HPV therapeutic vaccines and are in clinical trials. These 
strategies include peptide and protein vaccines, vector-based vaccines, and nucleic 
acid vaccines. Others such as whole-cell based vaccine, combinational approaches 
and prime-boost vaccination are also being studied. 
Peptide vaccines can be either: long peptides or short (specific epitopes) peptides. 
These vaccines are favoured because they are stable, safe and easy to develop (Hung 
et al., 2008b). However, their antigens are limited to a major histocompatibility complex 
(MHC) class I phenotype that is expressed by the patient (Su et al., 2010, Lin et al., 
2010). Furthermore, their immunogenicity is very low and must be administered with 
co-stimulatory molecules or adjuvants like Toll-like receptor (TLR) ligands (Yang et al., 
2016, Lin et al., 2010). Nonetheless, with adjuvants, peptide-based vaccines such as 
a synthetic long-peptide HPV 16 vaccine in incomplete Freund’s adjuvant and four 
HPV 16 synthetic peptide vaccines with Candida skin test reagent (PepCan) made it 
to clinical trials with significant cell mediated immune responses in cervical cancer 
patients (Coleman et al., 2016, Kenter et al., 2009). The utilization of peptide-based 
vaccines therefore depends on the improvement of their immunogenicity and antigen 
presentation (Bolhassani, 2018). 
Protein-based vaccines overcame the challenge of MHC class I molecule specificity 
because of the various number of epitopes, however they still need adjuvants due to 
their low level of immunogenicity (Lin et al., 2010). Additionally, their poor 
immunogenicity may  induce humoral rather than cell-mediated response (Su et al., 
2010). HPV protein-based vaccines have also advanced to clinical trials with the help 
of adjuvants and were noted to mount specific immune responses (Daayana et al., 
2010, Roman et al., 2007, Davidson et al., 2004, Frazer et al., 2004, Hallez et al., 
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2004). Notably, in a phase II trial, tissue antigen-cervical intraepithelial neoplasia 
vaccine (TA-CIN), has been shown to induce both the antibody and cellular (T-cell 
specific) mediated responses (Daayana et al., 2010). Furthermore, HPV-16 E7 
encoding a heat shock protein (Hsp) fusion protein vaccine (SGN-00101) induced 
lesion regression in correlation with immune responses in women with high-grade CIN 
(Roman et al., 2007). Interestingly, a plant-made HPV 16 therapeutic candidate 
vaccine (16E7SH) by our group showed significant cell-mediated immune response 
and tumor regression in mice (Whitehead et al., 2014). These data indicate that 
improving the immunogenicity of protein-based vaccine may lead to rapid eradication 
of lesion. Therefore, enhancing the immunogenicity of protein-based vaccine is the 
key to the usage of these vaccines. 
Researchers have also looked at vector vaccines, which are based on the modification 
of non-pathogenic viruses or bacteria that replicate inside the host cell and express 
antigens. Vectors like adeno-associated viruses (AAVs), vaccinia virus and Listeria 
monocytogenes have been used in the development of these vaccines. A single dose 
of recombinant AAV type 5 encoding HPV 16 L1 induced sufficient mucosal antibodies 
in vaginal washes and L1 specific serum antibodies in mice (Kuck et al., 2006). 
Interestingly after 60 weeks of immunization, cellular immunity was still detectable. 
Using  a vaccinia-based vaccine, HPV 16 E2- based vaccine effectively prevented 
HPV growth in high grade lesions (Rosales et al., 2014). Recombinant L. 
monocytogenes expressing HPV 16 E7 caused tumor growth regression in mice (Lin 
et al., 2002). However, there are concerns of safety, as these vaccines may pose 
danger in immunocompromised individuals (Lin et al., 2010).  
DNA vaccines have been extensively studied and gained traction as a foundation for 
HPV therapeutic vaccines. DNA vaccines are easy to manufacture, safe, stable and 
cause antigen-specific immunity (Lin et al., 2010, Gurunathan et al., 2000). 
Furthermore, DNA vaccines are not restricted to class I MHC molecules due to multiple 
epitopes and have unmethylated CpG motifs to act as adjuvants (Lin et al., 2010). The 
low level of immunogenicity has been improved by several strategies including the 
improvement of HPV antigen processing, expression and presentation in dendritic 
cells (DC), and increasing  the interaction between the DC and T cells (Tsen et al., 
2007). HPV DNA therapeutic vaccines such as pNGVL4a-CRT-E7(detox) and E6/E7 
vaccine known as GX-188E, advanced to clinical trials with robust cellular immune 
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response (Alvarez et al., 2016, Kim et al., 2014). Therapeutic vaccines are a promising 
approach to cancer treatment. Currently therapeutic vaccines are designed to induce 
antigen-specific cellular immunity and various clinical trials are underway to determine 
effective and safe vaccines. 
1.7 Plant expression systems 
Generally, the unaffordability of vaccines is due to their complex production systems 
(Daniell et al., 2009). Over the years, plants have gained traction as a cost-effective 
alternative to conventionally used expression systems (yeast, mammalian cells, 
bacteria and insects). Plant production platforms are rapid, affordable, easy to use and 
safe as they lack mammalian pathogens and toxins (Kushnir et al., 2012, Rybicki, 
2010, Fischer et al., 2004). Furthermore, plants have the eukaryotic machinery 
required for protein modification and folding (Fischer et al., 2004). 
Plant expression systems have been utilised since 1986, after a human growth 
hormone was produced in stably transformed tobacco and sunflower callus tissue 
(Barta et al., 1986). Shortly after, Hiatt et al. (1989) successfully produced a full 
monoclonal antibody in transgenic plants. Hepatitis B surface antigen was the first 
plant produced vaccine candidate (Mason et al., 1992). Since then various vaccine 
antigens have been effectively produced in plants. One of the recent breakthroughs in 
plant production is the quadrivalent VLP-based influenza vaccine candidate by 
Medicago Inc that is currently in the first phase III human trial. Data from phase II 
clinical trials demonstrated that the vaccine is safe and  induced consistent humoral 
and cellular immune responses in adults (Pillet et al., 2019).  The authors further noted 
that the vaccine is expected to elicit strong immune response in phase III clinical trial, 
data from this trial is expected to be available in coming months. 
Notably, in May 2012 the first plant-based enzyme replacement therapy was approved 
by the FDA for commercial use in humans (Fox, 2012). The enzyme, known as 
Elelyso™, is a recombinant glucocerebrosidase (GCD) used in Gaucher's disease 
treatment and is produced in transgenic carrot cells by Protalix Biotherapeutics and 
Pfizer (Carmiel, Israel). Gaucher is a lysosomal storage disorder (LSD) triggered by a 
lack of the GCD enzyme (Shaaltiel et al., 2007).  
Interestingly, during the 2014 West Africa Ebola outbreak, triple cocktail (2G4, 4G7, 
13C6) expressed in N. benthamiana was FDA approved for use to contain the Ebola 
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virus outbreak (Qiu et al., 2014). Furthermore, there are various plant produced 
antibodies, therapeutic proteins and vaccines that are in clinical development including 
Intrinsic factor for vitamin B12 deficiency, and Norwalk virus coat protein (CP)  
(reviewed in Yusibov et al. (2011)). All these data suggest that plant expression 
systems have the potential to develop affordable vaccines especially for use in 
developing countries. 
Plant expression systems are divided into two methods: transgenic or transient 
expression systems (Scotti and Rybicki, 2013). Traditionally, plant expression 
approaches relied on stably transformed plants, a genomic incorporation of a 
transgene into the plastid or nuclear  genome of the plant (Schillberg et al., 2005). 
Transgenic plants are obtained through gene delivery into monocots by means of 
biolistic or into dicots by Agrobacterium tumefaciens (A. tumefaciens) (Li et al., 1993, 
Mason et al., 1992). However, generating transgenic plants is a time consuming 
process (Huang et al., 2010, Schillberg et al., 2005).  
Transient expression of recombinant proteins recently became an alternative to 
transgenic expression systems. In contrast to stably transformed plants, transient 
expression systems can rapidly yield high levels of proteins in a very short time 
(Rybicki, 2010, Schillberg et al., 2005). Plant-based transient expression of 
heterologous recombinant proteins is accomplished by either the infection of plants 
with viral vectors from cowpea mosaic virus (CPMV) , Potato X virus (PVX) or tobacco 
mosaic virus (TMV) or by infiltration with recombinant Agrobacterium (agroinfiltration)  
(Varsani et al., 2006, Kapila et al., 1997).  With the viral vector approach, the gene of 
interest is cloned into the genome of the plant virus, with a strong subgenomic 
promoter. The resulting recombinant virus construct is then used to infect plants and 
deliver the transgene to the cell to yield the desired protein without having to stably 
transform the plant (Porta and Lomonossoff, 2002). Although this approach produced 
immunogenic protein, the expression levels of the protein of interest were relatively 
low compared to the transgenic plants (Turpen et al., 1995).  
These drawbacks caused the establishment of a new ideal strategy of deconstructed 
virus vectors and agroinfiltration (Marillonnet et al., 2005, Gleba et al., 2005). Altered 
plant viruses such geminiviruses, tobomaviruses, bromoviruses and bean yellow 
dwarf mastrevirus are commonly used in this approach. This approach uses the viral 
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replicative machinery, to synthesize non-infectious vectors that can induce transgene 
expression in plants (Gleba et al., 2005).  In our group, viral vectors such as pRIC, 
pTRA vector suit and pEAQ‐HT are used to transiently express pharmaceutically 
relevant recombinant proteins in plants (Chabeda et al., 2019, Gunter et al., 2019, 
Pineo et al., 2013, Regnard et al., 2010, Sainsbury et al., 2009, Maclean et al., 2007). 
Employing such vectors together with agroinfiltration results in higher levels of protein 
expression in a short period of time (3-7 days) compared to 6-9 months when using 
stably transformed plants (Tiwari et al., 2009, Gleba et al., 2005). Therefore, transient 
expression mediated by agroinfiltration via viral vectors is an ideal and cost-effective 
model for proteins production in plants (Rybicki, 2010). Notably, there is great potential 
to reduce high expenditure production of HPV VLPs and PsVs by using transient 
expression system (Santi et al., 2006). 
1.7.1 HPV VLPs and PsVs production in plants 
HPV VLPs have effectively been expressed in transgenic plants (Biemelt et al., 2003, 
Varsani et al., 2003, Warzecha et al., 2003). However, yields of VLPs were very low. 
Furthermore, early efforts to transiently express HPV VLPs in plants also resulted in 
very low expression levels and with mainly capsomeres and few VLPs (Varsani et al., 
2006).  
The work done by Varsani et al. (2006) laid the groundwork for further HPV research, 
particularly the production of VLPs in plants. Maclean et al. (2007) looked at plant, and 
human codon-optimization of HPV L1 gene and targeting of different cell 
compartments. The authors noted, high level of recombinant protein expression with 
fully assembled VLPs when using a human codon-optimized L1 gene as compared to 
plant codon-optimized L1 gene. Furthermore, protein expression was high when using 
a chloroplast-targeting vector than a cytoplasm-targeting vector. Their work 
demonstrated that plant transient-based expression system can be used to produce 
HPV VLPs. Utilizing the same approach Chabeda et al. (2019) and Pineo et al. (2013) 
successfully produced HPV 16 immunogenic L1 and L1/L2 chimaeric VLPs in plants. 
In both cases HPV16 L1 and L1/L2 chimaeric proteins were expressed at high levels 
using the pTRA-CTP vector, a non-replicating plant expression vector that targets the 
protein to the chloroplast.  
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PsVs have successfully been produced in N. benthamiana using human codon-
optimized L1 and L2 genes and a secreted alkaline phosphatase (SEAP) reporter 
plasmid (Lamprecht et al., 2016). The authors demonstrated that plant-produced HPV 
16 PsVs can be used in PBNA with comparable results to PsVs produced by 
mammalian cells.  This is a proof concept that plants may be used as a cost-effective 
alternative for PsV production. In conclusion, plants can potentially be used to develop 
safe, effective and affordable HPV vaccines especially for use in developing countries 
(Lamprecht et al., 2016). 
1.8 Rationale and objectives of the study 
Cervical cancer is a burden in developing countries with the highest prevalence 
reported in Africa. However, the costly production of commercially available HPV 
prophylactic vaccines is limiting their use in these countries. Furthermore, worldwide 
geographic distribution of HPV types differs, therefore the commercially available HPV 
vaccines will probably benefit some regions more than others. For instance, HPV 35 
is not available in any of the vaccines and is more dominant and important in Africa 
than other HPV types included in the current vaccines. Therefore, the current vaccines 
are partially ill-suitable for some regions. Ultimately, there is not only an urgent need 
to develop affordable HPV vaccines for use in developing countries, but these 
vaccines also need to address/include all carcinogenic HPV types that are important 
to these regions. Plants are a cost-effective alternative to widely used expression 
systems and have demonstrated their potential to make feasible and highly 
immunogenic vaccines with some FDA approved vaccines and some in human trials. 
Therefore, making multivalent HPV vaccines in plants will reduce the cost associated 
with current vaccines, and will particularly benefit resource-poor regions. 
This study aimed to evaluate the plant-based transient expression system as a tool to 
develop multivalent prophylactic HPV vaccines for use in developing countries, 
especially Africa which has the highest burden of cervical cancer. Furthermore, the 
study aimed to assess whether plant-produced VLPs can induce humoral responses 
in mice as effectively as the commercially available Gardasil® and if they are suitable 
prophylactic HPV vaccine candidates. To reduce the number of animals used in this 
study, only 3 HPV types that are important in Africa and are not included or partially 
protected by Gardasil®, were selected to immunize mice. 
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Specifically, the objectives of the study were as follows:  
1. To transiently express the L1 proteins of 8 most common high-risk HPV types 
in Africa, and 2 low-risk types (HPV 6, 16, 18, 31, 33, 34, 35, 45, 52 and 58) in 
N. benthamiana. 
2. Purification of putative plant-produced L1 VLPs proteins by density gradient 
centrifugation and TEM to determine if the expressed L1 proteins successfully 
assembled into VLPs. 
3. To vaccinate mice with selected plant-produced VLP vaccine candidates 
(produced in Objective 2) and Gardasil® (positive control) and to analyse the 
immunogenicity elicited by the vaccine candidates using ELISAs and to 



















2 Chapter 2: Transient expression and purification of HPV L1 VLPs in 
Nicotiana benthamiana 
2.1  Introduction 
The HPV L1 capsid protein can self-assemble into VLPs that are structurally and 
immunogenically similar to native virions (Jordan et al., 2019, Chabeda et al., 2019, 
Biemelt et al., 2003, Hagensee et al., 1993, Zhou et al., 1991). Interestingly, these 
VLPs can efficiently induce T-cell responses due to their particulate nature (Mohsen 
et al., 2019, Mohsen et al., 2018, Pineo et al., 2013). Furthermore, their surface has 
arrays of repetitive epitopes which are recognised by B cells, making these VLPs 
highly immunogenic compared to other sub-unit vaccines (Giannini et al., 2006). 
Notably, 3 HPV prophylactic vaccines based on L1 VLPs are commercially available 
and are effective at preventing HPV infections.   
HPV VLPs are produced in various systems, including: bacteria, yeast, insect-cell, 
mammalian and plants expression systems (Chabeda et al., 2019, Pineo et al., 2013, 
Maclean et al., 2007, Biemelt et al., 2003, Christensen et al., 1994, Kirnbauer et al., 
1992, Zhou et al., 1991). In bacterial expression systems, mostly Escherichia coli (E. 
coli), the virus capsid protein genes are codon-optimized for E. coli expression and 
are cloned in plasmids under strong promoters for increased protein expression  
(Brown et al., 2009b, Chen et al., 2000). HPV VLPs are produced by over-expressing 
the major L1 capsid protein in bacterial cells, followed by in vitro 
assembly/disassembly of purified L1 (Chen et al., 2001, Chen et al., 2000, Touzé et 
al., 2000). A disadvantage of using bacterially-produced VLPs is a safety concern as 
the recombinant proteins might contain endotoxins (Chen and Lai, 2013, Roldão et al., 
2010, Grgacic and Anderson, 2006). 
For production of the commercially available HPV L1 VLP-based vaccines; Gardasil®, 
Gardasil9® and Cervarix™, yeast and insect cells, respectively are used. These 
vaccines are produced by subjecting purified L1 to in vitro disassembly/reassembly 
treatments, which cause VLPs assembly and improve antigenicity, stability and 
structural integrity of VLPs (Zhao et al., 2014). These additional steps increase the 
already high expenditure of the overall production of VLPs in these systems (Chen 
and Lai, 2013). Mammalian expression systems  are another ideal choice to produce 
VLPs as they enable  post-translational modifications, which is crucial for the correct 
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folding of VLPs. , However this is a highly expensive system compared to other 
systems (Lai and Chen, 2012, Chen, 2008).  
Preventing HPV infections through vaccination significantly reduced cervical cancer 
death in developed countries. However, due to high cost associated with current HPV 
vaccines, this is still just a dream in developing countries (Mohsen et al., 2019, 
Waheed et al., 2016). Generally, the high costs of these vaccines are due to their 
complex production systems. Therefore, cost-effective alternative HPV vaccine 
production platforms need to be established for use in resource-poor countries. Over 
recent years, plants have gained traction as cost-effective alternative production 
systems for recombinant proteins 
Plant production platforms are safe, robust, highly scalable, with low production costs 
and have the eukaryotic machinery required for proper post translational modifications 
and assembly (Rybicki, 2010, Fischer et al., 2004).  Therefore, using plant platforms 
to produce vaccines might overcome the disease burden in developing countries.  
Plant expression systems can either be transgenic or transient. Recently, transient 
expression system gained attraction over stable transformed plants. This is because 
transient expression is in itself a contained system and can be used to rapidly produce 
large amount of proteins, thereby saving time  (Marsian and Lomonossoff, 2016, 
Fischer et al., 2012, Fischer et al., 2004). Transient expression is commonly achieved 
by introducing recombinant Agrobacteria harbouring a plant expression vector 
containing the gene of interest into plant leaves, mainly by syringe or vacuum 
infiltration, in a process known as agroinfiltration (Suzaki et al., 2019, Hoshikawa et 
al., 2019, Musiychuk et al., 2007). The process relies on the ability of A. tumefaciens 
to transfer the T DNA from the tumor inducing (Ti) plasmid into the cell nucleus of the 
plant (Tzfira et al., 2004). 
Studies that aimed to produce affordable HPV vaccines in plants mainly focused on 
the high-risk HPV 16 L1 and/or L1/L2 chimaeras (Chabeda et al., 2019, Zahin et al., 
2016, Pineo et al., 2013, De la Rosa et al., 2009, Fernández‐San Millán et al., 2008, 
Maclean et al., 2007, Varsani et al., 2006, Liu et al., 2005, Biemelt et al., 2003, Varsani 
et al., 2003) and low-risk HPV 11 L1 (Kohl et al., 2007, Warzecha et al., 2003), which 
have been shown to elicit strong immune responses in animals. This gave rise to this 
study to further investigate if VLPs for other important oncogenic HPV types could be 
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produced in plants. In this study, the production of affordable HPV vaccines in plants 
was of specific interest, with the focus on the oncogenic HPV types that are important 
in Africa. 
Figure 2.1 shows the prevalence of 8 most frequent high-risk HPVs in the world (A) 
and in Africa (B). HPV 35 is not included in any of the commercially available HPV 
vaccines and is more dominant and common in Africa. Worldwide, HPV 35 is the 8th 
most dominant high-risk HPV, while in Africa it is the 5th (Figure 2.1A and B 
respectively) (Smith et al., 2007c). Although relevant in an African context, HPV 16 
and 18 are included in Gardasil®, whereas high-risk HPV 31 is cross-protected by 
Gardasil® which is available for distribution in Africa (Brown et al., 2009a). For the 
remining HPV types (33, 45, 52 and 58), HPV 52 and 58 are among the most 
frequently reported high-risk in Sub-Saharan Africa (McDonald et al., 2014, Akarolo-
Anthony et al., 2013, Gage et al., 2012, Veldhuijzen et al., 2011). In Africa, HPV 58 
and HPV 52 are ranked 7th and 8th most prevalence high-risk HPVs, respectively 
(Figure 2.1B) (Smith et al., 2007c).  
 
Figure 2.1: Prevalence of 8 most common high-risk HPVs: A) Globally B) Africa. 
Data are based on 14 500 cervical cancer cases with 1 340 cases from Africa. Figure 
obtained with permission from Smith et al. (2007c). 
In an effort to develop a cost-effective HPV vaccine candidate, the L1 proteins of 8 
most frequent high-risk HPVs in Africa (HPV 16,18, 31, 33, 35, 45, 52, 58) (Figure 
2.1B) and 2 low risk types (HPV 6 and 34) were transiently expressed in N. 
benthamiana. Following successful expression of all the 10 HPV types in plants, 3 
oncogenic HPV types (HPV 35, 52 and 58) were selected to immunize mice and were 
quantified and prepared for animal studies (Chapter 3). Only 3 HPV types, that are 
relevant in an African context and are not included in Gardasil® or cross-protected by 
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this vaccine were selected for animal studies to minimize the number of animals used 
in this study.  
In conclusion, the L1 proteins of 10 HPV types were transiently expressed in N. 
benthamiana. Proteins were purified via isopycnic ultracentrifugation using sucrose 
and Optiprep™ density gradients, and the formation of VLPs assessed by TEM.  HPV 




















2.2 Materials and methods 
2.2.1 Bacterial strains 
Chemically competent E. coli DH5α (E. cloni®, Lucigen) and A. tumefaciens 
GV3101::pMP90RK were used in this study. All E. coli cultures were grown  overnight 
at 37°C with agitation in Luria-Bertani medium (LB; 1% sodium chloride [NaCl], 0.5% 
yeast extract and 1% tryptone) according to Sambrook et al. (1989).  Recombinant E. 
coli were cultured in the presence of 100µg/ml ampicillin to maintain selection 
pressure. A. tumefaciens was cultured in LB enhanced with 10mM 2-
morpholineethanesulforic acid (MES) and grown at 27°C with agitation. Transformants 
select on solid media plates were grown 2-3 days. For liquid cultures glycerol stocks 
were inoculated into 10ml LB supplemented with the relevant antibiotics and grown for 
overnight. This 10ml was used as inoculum for 50ml, which was in turn used to 
inoculate 500ml for large scale infiltrations. Recombinant A. tumefaciens constructs 
were selected and cultured in the presence of 30μg/ml kanamycin, 50μg/ml 
carbenicillin and 50μg/ml rifampicin. All bacterial cultures were preserved in a final 
concentration of 25% glycerol and stored at -80°C. 
2.2.2 Extraction, and purification of plasmid DNA; restriction enzyme digest 
and ligation 
In this study, all plasmid DNA extractions were isolated using the QIAprep® Spin 
Miniprep kit (Qiagen). Whereas, all DNA gel purifications were carried out using the 
QIAquick® Gel Extraction kit (Qiagen). Restriction enzymes and DNA ligase (T4) were 
from Fermentas (Thermo Fisher Scientific). The procedures of these experiments 
were all carried out as per the manufacturer’s instructions. 
2.2.3 Polymerase chain reaction and agarose gels 
All PCR reactions used to identify recombinant constructs were carried out using 
vector (pTRACTP) specific primers provided our laboratory (lab) (Table 2.1). 
Table 2.1: Primers used to confirm HPV constructs 
Primer name 5’-3’ primer sequence Length (bp) Tm (°C) 
pTRA-F CATTTCATTTGGAGAGGACACG 22 64 
pTRA-R GAACTACTCACACATTATTCTGG 23 64 
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In this study, all PCR reactions were carried out using ampliqon Taq DNA polymerase 
2x Master Mix Red (Thermo Fisher Scientific) and performed as stated in the 
manufacturer’s protocol, using 0.2μM of each primer and 2mM MgCl2. The reactions 
were carried out as follows: 1 cycle at 95°C for 5 minutes (denaturing step), then 30 
cycles at 95°C for 30 seconds (denaturing step), followed by annealing step at 59°C 
30 seconds and then extension step at 72°C for 30 seconds. An additional elongation 
step was carried out at 72°C for 5 minutes. No DNA template was used as a PCR 
negative control. All amplified PCR products were separated on 1% agarose gels, with 
O’GeneRuler™1kb DNA ladder (Thermo Fisher Scientific). 
2.2.4 Recombinant HPV plasmids 
All HPV L1 genes used in this study were synthesized by GenScript and were human 
codon optimized. A. tumefaciens GV3101::pMP90RK transformed with pTRACTP 
(used as negative control), a vector targeting expression of proteins to the chloroplast 
(Maclean et al., 2007) and the human codon-optimized HPV 6, 16, 34, 45, and 58 L1 
genes cloned into pTRACTP were obtained from the Biopharming research unit (BRU) 
culture collection. These recombinant plasmids were confirmed by colony PCR using 
the vector specific primers listed in Table 1 (Section 2.2.3). 
The other HPV L1 genes used in this study, HPV 18, 31, 33, 35 and 52, were obtained 
from GenScript in pUC57. All the genes contained 5’ MluI and 3’ Xhol restriction 
enzyme sites that allowed for subcloning into the pTRACTP plant expression vector. 
The L1 genes were excised from pUC57 using MluI/XhoI restriction enzymes and gel-
purified after which they were directly ligated into pTRACTP that was linearised with 
the same restriction enzymes. The ligated constructs were transformed into competent 
E. coli DH5α cells and incubated overnight at 37°C. Multiple single colonies were 
analysed by colony PCR as described in Section 2.2.3, to screen for pTRACTP-L1 
positive clones. 
2.2.5 Transformation of Agrobacterium  
The pTRACTP vector and pTRACTP-L1 plasmids for each HPV type was 
electroporated into electrocompetent Agrobacterium cells according to a method 
described by Shen and Forde (1989). Briefly, 100μl of competent Agrobacterium cells 
was mixed with 300ng of each recombinant pTRACTP-L1 HPV type in a 0.1cm 
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electroporation cuvette (Bio-Rad) and chilled on ice for 5 minutes. Cells were then 
electroporated at 200Ω, 1.8kV, and 25μF using a Gene Pulser XcellTM (Bio-Rad) after 
which 900µl of LB medium was added. Cells were then allowed to recover by 
incubating them at 27°C for 2 hours with gentle agitation before being plated onto LB 
agar plates supplemented with the appropriate antibiotics and incubated for 2-3 days. 
Colony PCR with the pTRACTP specific primers was carried out as described in 
Section 2.2.3 to confirm successful transformation of A. tumefaciens. To further 
confirm the recombinant L1 plasmids, DNA isolated from positive A. tumefaciens 
constructs were back-transformed into E. coli DH5α cells. Plasmid DNA isolated from 
recombinant E. coli was digested with MluI and Xhol restriction enzymes. 
2.2.6  Agrobacterium-mediated transient expression of N. benthamiana leaves 
Previous research conducted in the BRU had focused on optimization of HPV L1 
expression with the pTRACTP vector in N. benthamiana (Chabeda et al., 2019, 
Maclean et al., 2007). Therefore, the different HPV L1 proteins were expressed as 
follows:  plants were infiltrated at optical density of 0.5 (OD600=0.5) and biomass was 
harvested at 5 days post infiltration (dpi).  The same infiltration conditions were used 
for the negative control, pTRACTP.   
For large scale production of HPV VLPs, leaves of 6 weeks-old N. benthamiana (~40 
plants per HPV type) were vacuum infiltrated with the recombinant Agrobacterium 
cultures at a final OD600 of 0.5.  Briefly, 2ml of the recombinant Agrobacterium frozen 
glycerol stocks were revived by inoculating into 10ml LB medium supplemented with 
the relevant antibiotics and grown overnight with agitation. The following day, the 10ml 
pre-inoculums were inoculated into 50ml LB medium and grown overnight. The 50ml 
cultures were further scaled up the following day into a bigger flask containing 500ml 
LB supplemented with the relevant antibiotics (except rifampicin) and 20µM 
acetosyringone and grown overnight. Cultures were prepared for infiltration by diluting 
the 500ml overnight cultures to the required density of OD600 0.5 in resuspension buffer 
(5mM MES, 10mM MgCl2.6H20, pH 5.6), 200μM acetosyringone was added to the 
diluted culture. To allow induction of the vir genes by acetosyringone, diluted cultures 
were incubated at room temperature for an hour prior to infiltration. Plants were 
vacuum infiltrated with OD 0.5 of Agrobacterium culture using -100kPa vacuum 
pressure before releasing it.  Before and after infiltration plants were grown under the 
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following conditions: 22°C, 8 hours dark, and 16 hours of light. The pTRACTP negative 
control was treated and infiltrated in the same manner as all HPV constructs. 
2.2.7  Extraction and purification of VLPs 
Leaves were harvested 5 dpi and frozen at -80°C until protein extraction. For protein 
extraction, frozen leaves were homogenised with a T 25 digital Ultra-Turrax® (IKA® 
Works Inc) in 2x volumes of extraction buffer (1x High salt (0.5 M NaCl) Phosphate 
Buffered Saline, pH 7.4 [HSPBS]) (Maclean et al., 2007), with cOmpleteTM, 
ethylenediaminetetraacetic acid (EDTA)-free Protease Inhibitor and incubated at 4°C 
with agitation for 2 hours. To remove large plant debris, homogenates were filtered 
through 4 layers of 22-24μm pore MiraclothTM (MilliporeSigma) and further clarified by 
centrifugation for 15 minutes at 15 317 x g, 15°C in an Avanti centrifuge (Beckman).  
Clarified crude extracts were loaded onto 5ml 30% (w/v) sucrose cushion overlaid onto 
1ml 50% sucrose cushion in 38ml Ulta-ClearTM ultracentrifuge tubes and centrifuged 
for 45 minutes at 174 587 x g, 15°C using a SW32Ti rotor (Beckman). All sucrose 
solutions were prepared in 1x HSPBS. After centrifugation, the 30% cushions were 
collected with a long needle and the sucrose removed by dialysing the samples 
overnight at 4°C in 1x HSPBS with agitation. 
The following day, the dialysed samples were loaded onto discontinuous Optiprep™ 
(Sigma-Aldrich®) density gradients (5ml 27%, 4ml 33%, 2ml 39%, 1ml 50%) and 
centrifuged for 3 hours 30 minutes at 174 587 x g, 15°C using a SW32Ti rotor 
(Beckman). Optiprep™ is a sterile, endotoxin tested iodixanol-based gradient density 
medium, usually used for purification and isolation of macromolecules. Optiprep™ is 
obtained as a 60% iodixanol solution. To ensure that all the gradient steps contain the 
same PBS/NaCl concentration, a 50% Optiprep™ stock solution was made by diluting 
the Optiprep™ in 6x HSPBS. The 39%, 33% and 27% Optiprep™ steps were prepared 
from the 50% stock solution diluted with 1x HSPBS. The constant NaCl concentration 
maintained throughout the gradients ensures that the VLPs remain stable during 
purification. After centrifugation 1ml factions were collected from the bottom of the 
tubes by puncturing the lowermost part of the tube.  
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2.2.8 Protein analysis   
All the HPV L1 proteins were detected on western blots, however HPV 52 L1 proteins 
were analysed on Coomassie-stained sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE) since the rabbit-raised Gardasil® antiserum that was 
used to detect denatured HPV L1s in this study, unreliably detected HPV 52 L1s on 
western blot and there was no other antibody for detection of HPV 52 L1. The serum 
used in this study is not commercially available and was obtained by inoculating 
rabbits with Gardasil® by our lab. The serum has been tested and found to detect L1 
of HPV 6, 16, 18, 31, 33, 34, 35, 45, and 58 (Alta van Zyl, personal communication).   
Proteins were denatured by heating with 1x sample application buffer (SAB) (0,001% 
(w/v) bromothymol blue, 0.5M EDTA, 5% (w/v) SDS, 25% (v/v) glycerol) for 5 minutes 
at 95°C (Maniatis et al., 1982, Sambrook et al., 1989). The L1 proteins were resolved 
on 10% SDS-PAGE gels at 120V and either stained overnight at room temperature in 
Coomassie Blue stain (0.1% (w/v) brilliant blue G-250; 48% v/v methanol, 15% v/v 
glacial acetic acid) and then destained with destain solution (30% v/v methanol,10% 
v/v glacial acetic acid) overnight at room temperature.  For western blots SDS-PAGE 
gels were transferred for 90 minutes at 15V onto nitrocellulose membranes with a 
semi-dry transblotter (transBlot®, Bio-Rad). Membranes were blocked in blocking 
buffer (1x PBS; 5% long life fat-free milk, 1% Tween20) at room temperature for 30 
minutes with agitation. The membranes were probed with Gardasil® rabbit antiserum 
diluted in blocking buffer (1:2000 dilution) by incubating at 4°C for overnight with 
agitation. The blots were then washed 4 x 15 minutes in blocking buffer and incubated 
for 1 hour at 37°C with anti-rabbit IgG alkaline phosphatase-conjugated secondary 
antibody (Sigma-Aldrich®) diluted in blocking buffer (1:5000) with shaking. After 
incubation with the secondary antibody the membranes were washed 4 x 15 minutes 
with blocking buffer not containing milk. L1 proteins were detected after incubating the 
membranes with 5-bromo-4-chloro-3-indoxyl-phosphate (BCIP) and nitroblue 
tetrazolium (NBT) phosphatase substrate (BCIP/NBT 1-component) (Whitehead 
Scientific) for 30 minutes.   
2.2.9 Transmission electron microscopy  
TEM was used to determine if the expressed L1 proteins fully assembled into VLPs. 
A Model 900 SmartSet Cold Stage controller (Electron Microscopy Sciences) was 
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used to glow discharge carbon-coated copper grids (mesh size 200) at 25mA for 30 
seconds. Samples were trapped onto the grids by floating the grids, carbon side down, 
on the sample for 4 minutes.  Thereafter, the grids were washed 4x with deionised 
water and negatively stained for 1 minute with 2% w/v uranyl acetate. Grids were air-
dried and viewed with a FEI Tecnai 20 transmission electron microscope.  
2.2.10 Vaccine candidates 
2.2.10.1 Detection of selected vaccine candidates with monoclonal 
antibodies 
As described in Section 2.1, HPV 35, 52 and 58 were selected for the immunogenicity 
study (Chapter 3). Therefore, conformation and structural integrity of HPV plant-
produced VLP vaccine candidates were further analysed by carrying out dot blots, 
using type-specific monoclonal antibodies (MAbs) from Dr Neil Christensen (Penn 
State Cancer Institute) (Table 2.2) that detect intact proteins. These MAbs bind to the 
conformational epitopes on the surface of non-denatured VLPs and/or capsomeres. 
Therefore detection of L1 by these types partially suggest correct folding and assembly 
of particles that display conformational epitopes (Christensen et al., 1996a). Purified 
empty vector pTRACTP was used as negative control. Additionally, each HPV type 
was probed with all 3 type-specific MAbs, to ensure there was no cross-contamination 
during sample preparation.  
 A volume of 2µl of purified plant-produced VLPs and negative control pTRACTP was 
added on the nitrocellulose membrane and left to air-dry. Membranes were then 
blocked with blocking buffer for 30 minutes with agitation. Membranes were probed 
with type-specific primary MAbs (table 2.2) diluted in blocking buffer (1:1000) and 
incubated at 4°C overnight with agitation. The blots were washed 4 x 15 minutes in 
blocking buffer and incubated for an hour with agitation at 37°C with anti-mouse IgG 
alkaline phosphatase-conjugated secondary antibody (Sigma-Aldrich®) diluted in 
blocking buffer (1:5000). Afterward, the membranes were washed 4 x 15 minutes with 
blocking buffer without milk. Protein was detected by incubating the membranes with 




Table 2.2: Monoclonal antibodies used to detect purified plant-produced HPV vaccine 
candidates 
HPV types MAbs 
HPV 35 H35Q8 
HPV 52 H52D11 
HPV 58 H58 J6.3 
2.2.10.2 Protein quantification of selected vaccine candidates 
Gel densitometry was used to quantify plant-produced HPV vaccine candidates. 
Bovine serum albumin (BSA, (Sigma-Aldrich®)) was used as protein standard.  BSA 
(1mg/mL) was diluted 2-fold in PBS to generate a standard curve. BSA standards and 
25µl of samples containing VLPs were mixed with 1x SAB and denatured at 95°C for 
5 minutes. A volume of 25µl of the standards and the samples were loaded onto a 
10% SDS-PAGE gel. The gel was Coomassie-stained and destained as described in 
Section 2.2.8. Quantification of the protein bands was carried out with StudioTM Lite 
version 5.2 software (LI-COR®). 
After quantification, the concentration needed for mice vaccinations was calculated for 
each type. Samples were pooled and then aliquoted into volumes enough for each 
injection. Samples were tested for endotoxin using ToxinSensorTM chromogenic LAL 
endotoxin assay kit (GenScript) as per manufacturer’s instructions. Furthermore, 
samples were grown overnight on LB agar at 37°C without antibiotics and observed 
for any viable bacterial growth before they were stored at -80°C until animal studies. 








2.3.1 Recombinant HPV plasmids 
A. tumefaciens transformed with human codon-optimized HPV 6, 16, 34, 45, and 58 
L1 genes already cloned into the pTRACTP plant expression vector were provided by 
our lab and confirmed by colony PCR (Figure 2.2A). L1 positive clones are indicated 
by the presence of bands at ~1500 base pairs (bp) (black arrow, Figure 2.2A). As 
expected, the empty vector yielded a product at ~300 bp (blue arrow), and no band 
was observed in the PCR negative control (Figure 2.2A). Meanwhile, human codon-
optimized HPV 18, 31, 33, 35 and 52 L1 genes were excised from pUC57 with 
MluI/XhoI restriction digestion and sub-cloned into pTRACTP. Recombinant 
pTRACTP-HPV L1 plasmids were transformed into competent E. coli DH5α cells and 
confirmed by colony PCR (Figure 2.2B) before electroporation into A. tumefaciens 
GV3101::pMP90RK. For E. coli and Agrobacterium, all selected colonies tested 
positive for the presence of L1, as indicated by the expected band size of ~1500bp 
(black arrow, Figure 2.2B and C, respectively). Furthermore, no band was observed 
in the no template PCR negative control for both E. coli DH5α and Agrobacterium 
transformation (Figure 2.2B and C, respectively). Restriction enzyme digests were 






Figure 2.2: Colony PRC of recombinant pTRACTP-HPV L1 genes: A) confirmation 
of HPV L1 clones in Agrobacterium obtained from BRU culture collection; B) Colony 
PCR confirming successful E. coli transformation and Agrobacterium transformation 
(C). The presence of PCR fragments at ~1500 bp (black arrows) indicate L1 positive 
clones. As expected, the empty vector yielded approx. 300 bp product (A, blue arrow) 
and no bands were observed in the PCR negative controls. Labels: -VE: no DNA 
template PCR control; EV: empty pTRACTP vector; Numbers 1-6 and 1-3 - selected 
colonies of each HPV type; M: DNA ladder with sizes indicated in base pairs. 
2.3.2 Large scale expression of HPV L1 proteins in N. benthamiana 
The aim was to evaluate plant-based transient expression as a tool for making L1 
VLPs of HPV 6, 16, 18, 31, 33, 34, 35, 45, 52 and 58 that are potentially suitable for 
making affordable prophylactic HPV vaccines, especially for use in developing 
countries. To date, plant-based studies have been focusing mainly on the 
development of HPV 16 L1 and L1/L2 VLPs in plants. This gave rise to this study, 
which investigated the expression of VLPs for other oncogenic HPVs in plants. 
Expression of HPV L1 genes in N. benthamiana, was previously optimized by our lab 
(Chabeda et al., 2019, Maclean et al., 2007). Large scale expression studies were 
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performed by vacuum infiltration with recombinant Agrobacterium culture at a final 
OD600 of 0.5. At 5 dpi all plants looked relatively healthy with the development of slight 
chlorosis in plants infiltrated with HPV L1 as compared to empty vector, no tissue 
necrosis was observed. Figure 2.3 shows representative phenotypes of leaves 
infiltrated with selected vaccine candidates (A-B) and empty vector (D). Leaves of 
plants infiltrated with HPV L1 had a slight change in colour to pale yellow (Figure 2.3A-
C) when compared to those infiltrated with empty vector (Figure 2.3D). Leaves of 
plants infiltrated with other 7 HPV types had similar phenotypes as that observed for 
vaccine candidates. Leaves were harvested 5 dpi and frozen at -80°C until extraction 
and purification. 
    
Figure 2.3: Phenotype of infiltrated plant leaves: A-C) leaves of HPV 35, 52 and 
58, respectively; D) Empty vector. All plants were infiltrated at OD600 0.5 and harvested 
5 dpi. 
2.3.3 Purification and analysis of HPV L1 proteins 
To assess if L1s were expressed in tobacco plants, leaves were extracted and purified 
as described in Section 2.2.7. Expression of L1s were determined by their 
sedimentation in Optiprep™ step-gradients, detection by rabbit-raised Gardasil® 
antiserum on western blots and Coomassie-blue staining in the case of HPV 52. 
Prior to purification of the L1 VLPs on Optiprep™ step-gradients, crude L1 plant 
extracts were concentrated in 30% sucrose cushions, Section 2.2.7. The 30% sucrose 
cushioned samples of all HPV types appeared green after centrifugation (yellow arrow, 
Figure 2.4A and B). The 30% sucrose fractions were collected from the tubes and 
dialysed overnight. The dialysate was further purified on discontinuous Optiprep™ 
gradients. After centrifugation a green band at or above the 27% step was observed 
(green arrow, Figure 2.4C and D), potentially indicating that co-extracted plant proteins 
are contained at the top of the gradient. A light brown band was observed in the 33% 
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and 39% Optiprep™ fractions (yellow arrow, Figure 2.4C and D), where assembled 
HPV particles were expected to occur. There was no pellet observed after 
ultracentrifugation. A volume of 1ml fractions were collected from the bottom of the 
tubes and analysed on western blots and Coomassie-stained gels in the case of HPV 
52.  
Initially it was attempted to concentrate plant-purified fraction on a second, smaller 
step gradient by banding the VLPs onto the 50% Optiprep™ fraction according to the 
method described by Chabeda et al. (2019).  This however did not yield consistent 
results, therefore Optiprep™ steps making up the discontinuous gradients were halved 
in volume and finally 500 µl fractions were collected from the tubes. 
 
Figure 2.4: Purification of plant produced HPV VLPs: Photos and schematic 
representations of, A-B) sucrose cushion (30% and 50 %); C-D) OptiprepTM gradient 
(50%, 39%, 33% and 27%). Labels: yellow arrows-VLPs; green arrows-native plant 
proteins. 
Western blot analysis with Gardasil® antiserum of fractions collected after 
centrifugation showed the presence of bands at ~56 kDa from fraction 2 onward, 
indicating the presence of HPV L1 after purification (yellow arrows, Figure 2.5A-J).  
Except in the case of HPV 16, 31, 34, 35 and 58 L1 was detected from fraction 1 
onward. This possibly indicated the co-purification of VLPs and/or capsomeres or 
aggregates of L1 of dissimilar densities. For HPV 16, 18, 31, 35 and 58 a second band 
was detected at ~46 kDa, indicating potential cleavage products of L1 (black arrows, 
Figure 2.5B-D, G and I). By comparing the intensity of the bands on individual western 
blots, it is evident that lower expression levels of HPV 33 and HPV 45 L1 was obtained 
compared to the other HPV types. However, fraction 4 of all HPV types, except for 
HPV 52 were all analysed on one blot, which indicated the presence of L1 at ~56 kDa 
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with similar band intensity for all types (Figure 2.5J). Furthermore, the blot indicated 
that HPV 6, 16, 18, and 45 L1s run higher on western than other types. 
HPV 52 was analysed on Coomassie-stained SDS-PAGE only, because there was no 
antibody to reliably detect HPV 52 L1 on western blot. The Coomassie-stained gel 
indicated the presence of HPV 52 L1 at ~56 kDa from fraction 2 onwards (Figure 2.5K). 
The empty vector (pTRACTP) negative control was analysed on a western blot and 
Coomassie-stained gel, as expected no L1 bands were observed on the western blot 
(Figure 2.5L). Two bands ~59 and 55 kDa were observed in fraction 9 of the 
Coomassie-stained gel, possibly indicating the presence of native plant proteins, such 






Figure 2.5: Analysis of plant produced HPV VLPs: A-I) individual HPVs western 
blots; J) western blot of all HPV types; K) Coomassie-stained gel for HPV 52; L-M) 
western blot and Coomassie-stained gel for the empty vector, respectively. Purified 
HPV L1 proteins (~56 kDa) were probed with anti-Gardasil® (1:2000 dilution) and anti-
rabbit IgG alkaline phosphatase-conjugated secondary antibody (1:5000). Labels: M: 
pre-stained protein standard (kDa); yellow arrows: HPV L1 protein (~56 kDa); black 
arrows: potential L1 cleavage products (~46 kDa); green arrows: native plant proteins.   
2.3.4 Transmission electron microscopy analysis 
After successful expression of HPV L1s in N. benthamiana, the next step was to 
assess whether the L1 proteins successfully assembled into VLPs. This was achieved 
by trapping samples onto carbon-coated copper grids and viewed under TEM. TEM 
analysis showed that VLPs were mostly observed in 33 and 39% Optiprep™ (fractions 
3-6). Figure 2.6 shows the TEM representative of fractions which had  better looking 
VLPs, fraction 3 for HPV 16, 34, 35 and 45; fraction 4 for HPV 6, 52 and 58; and 
fraction 5 for HPV 18, 31 and 33. For all the HPV types expressed, TEM analysis 
showed fully assembled spherical VLPs of 40-60nm diameter (yellow arrows), small 
VLPs and/or capsomeres of 25-39nm diameter (blue arrows) and L1 aggregates 
(black arrows) (Figure 2.6). HPV L1 has been shown to assemble into particles of 
different sizes, varying from 25-60nm (Chabeda et al., 2019, Pineo et al., 2013, Kim 
et al., 2010, Maclean et al., 2007, Biemelt et al., 2003). 
By comparing VLPs per field of view HPV 6, 16, 35, 45, 52 and 58 appeared to be 
populated by fully assembled VLPs (40-60nm) as compared to HPV 18, 31, 33, and 
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34 which were mostly populated by capsomeres and aggregates. Furthermore, HV 52 
and 58 made particles with better structural integrity than other types.  The population 
of fully assembled particles decreased across the fractions, less dense gradient 
fractions (F7-9) were mostly populated by L1 aggregates. No structures resembling 
VLPs and/or capsomeres were observed in the negative control, structures seen in 
the negative control is probably plant aggregates (venetian red arrow, Figure 2.6).   
   




    




    
 
Figure 2.6: Electron micrographs of purified plant-produced L1 antigens: 
Samples were purified on Optiprep™ density gradients and viewed under EM at the 
magnification of 40 000 X. Bars are 200nm in size. Labels: yellow arrows: VLPs; blue 
arrows: small VLPs and/or capsomeres; black arrows: L1 aggregates; venetian red 
arrow: native plant aggregates. 
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2.3.5 Vaccine candidates 
2.3.5.1 Detection of selected vaccine candidates with monoclonal antibodies 
After showing that L1 successfully assembled into VLPs, I wished to determine 
whether the observed VLPs can induce an immune response in an animal model. 
However as explained in Section 2.1, only HPV 35, 52 and 58 were selected for the 
animal study. VLPs/capsomeres of vaccine candidates were tested to determine 
whether they displayed conformational epitopes, which usually results in high titres of 
neutralizing antibodies (Kirnbauer et al., 1992). 
The structural integrity and conformation of VLPs/capsomeres for selected vaccine 
candidates were tested by carrying out dot blots using type-specific monoclonal 
antibodies (Section 2.2.10.1, Table 2.2 ) which bind to the conformational epitopes on 
the surface of undenatured L1 VLPs and/or capsomeres (Christensen et al., 1996a). 
To ensure there was no cross-contamination during sample preparation, each HPV 
type was probed with all three type-specific MAbs. As expected, type specific 
monoclonal antibodies detected corresponding HPV L1 proteins (Figure 2.7), 
indicating that samples were not cross-contaminated. However, H35Q8 and H52D11 
antibodies weakly reacted with HPV 58 and HPV 35 L1, respectively (Figure 2.7A and 
B). This suggested potential cross-reactivity due to shared conformational epitopes 
between these types. Detection of HPV L1s by these antibodies confirmed the 
presence of assembled particles displaying surface conformational epitopes in the 
samples. As expected, the antibodies did not bind to the purified negative control 
(empty vector) samples (Figure 2.7). 
 
Figure 2.7: Dot blots of vaccine antigens: L1 proteins were detected using type 
specific monoclonal antibodies: HPV 35: H35Q8; HPV 52: H52D11; HPV 58: H58J6.3. 
All the antibodies were used at a dilution of 1:1000, followed by probing with anti-
mouse IgG alkaline phosphatase-conjugated secondary antibody (1:5000).  Labels: -
ve: negative control (empty vector).  
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2.3.5.2 Quantification of vaccine candidates 
Selected vaccine candidates were quantified to determine the amount of VLPs and/or 
capsomeres present in the samples. Efforts to concentrate VLPs did not yield 
consistent results, therefore discontinuous gradients were halved in volume and 500µl 
fractions were collected. Fractions 3-5 (33% and 39% OptiprepTM) had the best looking 
VLPs and/or capsomeres for the selected vaccine candidates. Therefore, they were 
each quantified using gel densitometry, with BSA as protein standard (results not 
shown) to determine the approximate VLPs/capsomeres in each fraction.  
Total VLP and/or capsomere yields per kilogram (kg) of fresh weight biomass of at 
least ~7.28mg/kg, 5.44mg/kg and 4.36mg/kg were obtained from fractions 3-5 for HPV 
35, 52 and 58 respectively. After the concentration needed for mice vaccinations was 
calculated for each type, samples were pooled and tested for bacterial endotoxin level. 
Approximately 14EU/ml was estimated in the empty vector sample, whereas VLPs 
sample had a slightly higher level of 50EU/ml. This amounted to a total of ~0.84EU 
and 3EU per injection of empty vector and VLPs sample respectively. Furthermore, 
samples were grown overnight on LB agar plates to ensure no viable bacterial growth 
present, which might negatively affect the immune response and cause harm to the 














Commercially available prophylactic HPV vaccines are effective at preventing HPV 
infections (McClymont et al., 2019, Wilkin et al., 2018, Lin et al., 2010, Moodley et al., 
2006). However, the cost associated with the commercially available HPV vaccines is 
preventing their use in developing countries especially Africa, where the highest 
burden of cervical cancer is reported (Liu et al., 2005, Taira et al., 2004). A multivalent 
vaccine targeting all HPVs that are important and more dominant in Africa may 
alleviate the high cervical burden reported in this region.  Plants have been utilized 
with the hope of producing affordable vaccines and might overcome the disease 
burden in developing countries (Rybicki, 2010, 2009, Liu et al., 2005). Plants produced 
vaccines can potentially reduce the estimated vaccine cost with up to 31% at the 
production level (Rybicki, 2009). For these reasons, efforts to develop affordable HPV 
vaccine candidates in plants are under way.   
HPV 16 L1 and/or L1/L2 chimaeric VLPs have successfully been transiently expressed 
in plants and have been shown to elicit immune response in animal models (Chabeda 
et al., 2019, Pineo et al., 2013, Fernández‐San Millán et al., 2008, Maclean et al., 
2007, Varsani et al., 2006). In this study, transient expression of human codon-
optimized HPV L1 genes in N. bethamiana was utilized to develop HPV L1 VLPs, that 
will potentially be used for making affordable multivalent prophylactic HPV vaccines, 
for use in developing countries. Five days post infiltration, plants looked healthy with 
minimum if any, chlorosis observed (Figure 2.3). These findings were similar to 
research done by  Chabeda (2017), where expression of HPV 16 L1 and  L1:L2 
chimaeras with the same vector used in this study (pTRACTP) resulted in increased 
protein expression with minimal development of chlorosis and necrosis. 
Purity and efficaciousness are essential when preparing VLPs for vaccination 
purposes (Vicente et al., 2011). Therefore, robust downstream processing of VLP-
based vaccines is crucial. Density gradient ultracentrifugation is regularly used for the 
purification of VLPs from several expression systems at the laboratory level.HPV VLPs 
have been purified by ultracentrifugation in other studies (Chabeda et al., 2019, 
Minkner et al., 2018, Jiang et al., 2011, Park et al., 2008, Maclean et al., 2007, Buck 
et al., 2005a). In the present study, plant-made VLPs were purified in two steps, firstly 
by concentrating the VLPs present in the crude plant extract in a 30% sucrose cushion.  
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In the second step the dialysed 30% sucrose fractions were loaded onto Optiprep™ 
step gradients to enable for the purification of HPV VLPs based on their buoyant 
density, isopycnic centrifugation (van Zyl and Hitzeroth, 2016).  
After ultracentrifugation, successful separation of plant proteins from HPV L1 VLPs 
were obtained in that plant proteins were detected in fractions 8 and 9 (27% 
Optiprep™, Figure 2.5M), this was also evidenced by the presence of a green band at 
or above the 27% step in the Optiprep™ gradient (Figure 2.4C and D). These results 
are consistent with previous results obtained in our lab.  In Chabeda et al. (2019),  a 
low pH buffer was used for purification of chimaeric VLPs, and although the low pH 
buffer is effective in reducing the amount of host cell proteins co-purified with L1, it 
also results in significant L1 losses compared to purification of L1 VLPs in neutral pH 
buffer. These indicate that there is still much to be done to improve purification 
techniques of plant-made HPV VLPs. 
The presence of bands ~56 kDa on western blots and Coomassie-stained gel in the 
case of HPV 52 (Figure 2.5), indicated successful expression and purification of the 
L1 capsid protein in N. bethamiana. These results are consistent with other studies 
(Chabeda et al., 2019, Pineo et al., 2013, Fernández‐San Millán et al., 2008, Maclean 
et al., 2007, Biemelt et al., 2003). Furthermore, potential cleavage products of L1 
(bands ~46 kDa) were observed on westerns with some HPV types (black arrows, 
Figure 2.5). Protein degradations within tobacco plants have been reported in other 
studies (Chabeda et al., 2019, Veerapen et al., 2018, Fernández‐San Millán et al., 
2008, Sharp and Doran, 2001, De Neve et al., 1993). Protein degradation may be 
explained by thousands of proteases such as: cysteine proteases present in plants. In 
plants, proteins are degraded either inside the cells by intracellular proteases or 
outside by extracellular proteases (Doran, 2006, Sharp and Doran, 2001). Among 
other proteases, the genome of tobacco is known to code for a minimum of 60 putative 
cysteine proteinases (CysPs), which might be involved in protein degradation (Duwadi 
et al., 2015, Hao et al., 2006). 
TEM analysis showed fully assembled VLPs measuring 40-60nm in diameter as well 
as small VLPs and/or capsomeres measuring 25-39nm (Figure 2.6).  L1 aggregates 
were also observed under TEM.  HPV L1 has been shown to assemble into particles 
of different sizes, varying from 25-60nm in different expression systems, including 
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plants  (Chabeda et al., 2019, Pineo et al., 2013, Kim et al., 2010, Maclean et al., 2007, 
Kohl et al., 2007, Biemelt et al., 2003). Full sized (40-60nm) and small (25-39nm) plant-
produced HPV 16 L1 VLPs have been observed in the chloroplast (Chabeda et al., 
2019, Pineo et al., 2013, Maclean et al., 2007, Biemelt et al., 2003). The presence of 
L1 aggregates after purification was not surprising as it appears that recombinantly 
produced HPV L1 is prone to aberrant assembly, as the presence of aggregates have 
been reported on in other research (Chabeda et al., 2019, Maclean et al., 2007, Kohl 
et al., 2007, Biemelt et al., 2003). However, formation of L1 aggregates may not be 
unique to plants, HPV VLPs in other expression systems - yeasts and insect cells are  
made by in vitro disassembling/reassembling of purified L1 to get  a homogenous 
population of VLPs, suggesting the formation of aggregates by these systems (Zhao 
et al., 2014).. Therefore, plant transient-based expression system can be used as a 
tool for making cost-effective HPV L1 VLPs that can potentially be explored to make 
prophylactic HPV vaccines. 
After successful expression of the 10 HPV L1 VLPs in tobacco plants, the second step 
was to test whether these VLPs are appropriate for the development of affordable HPV 
prophylactic vaccines. However, to reduce the number of animals used, only 3 plant-
produced HPVs (35, 52 and 58) were selected for mice studies (Chapter 3). These 
types have been selected mainly for their importance in Africa, especially Sub-
Saharan Africa as described in section 2.1. HPV L1 VLPs selected for mice 
immunization experiments were then further analysed by probing with type-specific 
conformational antibodies on dot blots (Figure 2.6).  Detection of the proteins by these 
antibodies confirmed that even though a homogenous population of VLPs was not 
obtained after purification, conformational epitopes were displayed on the VLPs and/or 
capsomeres present in the purified samples. This suggested the potential of these 
VLPs to induce immune response, therefore preventing HPV infection. 
Selected HVP vaccine candidates were quantified using gel densitometry. Prior to 
storage of the vaccine candidates at -80 °C, 2 bands at 56 and 46 kDa were observed 
on western blots for HPV 35 and HPV 58 (Figure 2.5G and I).  The lower molecular 
weight band observed on blots could have been due to cleavage of L1 proteins by host 
cell proteases such as cysteine proteases.  In the case of HPV 52 no lower molecular 
weight band was observed immediately after extraction and purification however, after 
freezing and thawing, the lower molecular band was observed (results not shown).  
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This indicated degradation of L1 protein during storage, which was also reported on in 
Pineo et al. (2013). The expected L1 band at 56 kDa and the lower molecular weight 
band at 46 kDa were quantified to obtain the total amount of L1 VLPs and/or 
capsomeres present in collected fractions with best looking VLPs based on TEM 
micrographs.  
In this study, expression of human codon-optimized HPV L1 genes resulted in 
accumulation of HPV L1 VLPs in the chloroplast. Efforts to concentrate HPV L1 did 
not yield consistent results, therefore the total L1 yields were not determined in this 
study. However, total VLP yields per kg of fresh weight biomass of at least 
~7.28mg/kg, 5.44mg/kg and 4.36mg/kg were obtained from fractions 3-5 for HPV 35, 
52 and 58 respectively. Total L1 yield of 533mg/kg and 142mg/kg was reported by 
other researchers when codon-optimized HPV 16 L1 genes were transiently 
expressed in tobacco using chloroplast-targeted vectors (Chabeda et al., 2019, 
Maclean et al., 2007). Fernández‐San Millán et al. (2008) reported the total L1 of 
3000mg/kg in tobacco plants. The higher expression level was achieved using HPV 
16 L1 fused to the 5′‐untranslated region (5′‐UTR) of the psbA gene of the pAF vector 
to transform tobacco chloroplast.  The authors noted that 5’-UTR might have caused 
high translation rate, which might explain the higher expression level achieved 
compared to other studies.  
Early efforts to produce affordable HPV vaccines in plants included the expression of 
humanized codon-optimized HPV 16 L1 gene and  plant-codon optimized HPV 11 L1 
gene in transgenic tobacco and potato (Biemelt et al., 2003, Warzecha et al., 2003). 
Although HPV L1 genes successfully assembled into immunogenic VLPs, the 
expression level was very low. Varsani et al. (2006) transiently expressed native HPV 
16 L1 genes in N. benthamiana, however the expression level was still low. 
Maclean et al. (2007) compared plant and human codon optimized HPV L1 genes. 
The study showed that the expression of human codon optimized HPV L1 genes 
ensured optimal usage of transfer ribonucleic acid (tRNA) and translation by plant 
cellular machinery and therefore resulted in high protein expression levels. Whereas 
the expression of plant codon-optimized L1 gene did not yield detectable L1 protein 
(˂1mg/kg of plant biomass). Furthermore, targeting the protein to different plant cell 
compartments influenced protein expression. Maclean et al. (2007) showed that when 
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the proteins were targeted to the chloroplast a yield of 533mg/kg was achieved, 
whereas when they were targeted to the cytoplasm a lower yield of 379mg/kg was 
observed. 
Increased accumulation of recombinantly expressed HPV L1 proteins in the 
chloroplast has also been reported by other researchers (Chabeda et al., 2019, Zahin 
et al., 2016, Pineo et al., 2013, Fernández‐San Millán et al., 2008). Additionally, 
expression of Type I interferons ‐α2b, cholera toxin B (CTB) fusion proteins, Anthrax 
protective antigen, and CTB subunit gene in plants resulted in high level of protein 
expression in the chloroplast  (Arlen et al., 2007, Limaye et al., 2006, Watson et al., 
2004, Daniell et al., 2001). Apart from high translation rate by 5′‐UTR in the vector as 
reported by Fernández‐San Millán et al. (2008), the increased level of protein 
accumulated in this organelle  may be explained by diverse protein hydrolysis, low 
level of cell toxicity, stable messenger RNA (hence stable L1 protein in this case), and 
low level of proteases in this compartment (Maclean et al., 2007). Consequently, high 
expression levels of HPV L1s recently achieved when targeting the chloroplast 
illustrate that tobacco plants are a promising system to produce affordable HPV 
vaccines for use in resource-poor countries. 
In conclusion, the major L1 capsid protein of 10 HPV types were successfully 
expressed in N. bethamiana and purified by density gradient ultracentrifugation. TEM 
analysis of the purified L1 proteins showed the successful assembly of VLPs for all 10 
HPV L1 types. Three HPV types (35, 52 and 58) were selected and prepared for mice 
immunization studies (chapter 3). The study has demonstrated that transient 
production of HPV L1 VLPs in tobacco plants, can potentially be used to develop 
affordable HPV prophylactic vaccines. This is the first study that expressed 10 HPV 
L1s in plants, marking a step towards the development of cheaper multivalent HPV 







3 Chapter 3: Immunogenicity of plant-made HPV VLPs in mice 
 
3.1 Introduction  
Vaccination is the most effective approach in preventing viral diseases. It results 
specifically in a humoral immune response with neutralizing antibodies, that enable 
the prevention of infections (Schiller and Lowy, 2018). HPV VLPs are structurally 
identical to native virions and most importantly they display high density of 
conformational and/or linear neutralizing epitopes (Grgacic and Anderson, 2006). HPV 
VLPs are effective at preventing infections and is the foundation onto which 
commercially available vaccines have been developed. 
Three prophylactic VLPs-based HPV vaccines are commercially available- Gardasil®, 
Cervarix™ and Gardasil9®. Gardasil® targets HPV 6, 11, 16 and 18, whereas 
Cervarix™ protects against HPV 16 and 18 infections (Schiller et al., 2008). Gardasil9® 
targets a wide spectrum of HPV types (HPV 6, 11, 16, 18, 31, 33, 45, 52 and 58) 
(Petrosky et al., 2015). These vaccines are all formulated in aluminum-based 
adjuvants and studies have demonstrated that they are highly effective and safe. 
Significant reduction in high-grade cervical abnormalities and genital warts have been 
reported in Australia since the government introduced national vaccination programme 
with Gardasil® for women aged 12–26 years (Brotherton et al., 2011). While, 
vaccination of women aged 16-24 years with Cervarix® reduced the prevalence of HPV 
16 and 18 from 19.1% to 6.5 % in England (Mesher et al., 2013).  
Studies focusing on the safety of Gardasil® and Cervarix™ vaccines, concluded that, 
they are safe and well-tolerated (Clark et al., 2013, Roteli-Martins et al., 2012, 
Gasparini et al., 2011, Block et al., 2010, Didierlaurent et al., 2009). Gardasil9® has 
been shown to prevent  persistent infections and vaginal, vulvar and cervical diseases 
caused by the HPV types included in the vaccines  (Joura et al., 2015). Although the 
current commercially available HPV vaccines are effective at preventing HPV 
infections, the high costs associated with these vaccines prevents vaccination 
programmes in developing countries, where they are most needed (McKee et al., 
2015, Biemelt et al., 2003). For example, Africa has the highest burden of cervical 
cancer (Ginsburg et al., 2017), yet only 1-2% of girls aged 10-20 years get vaccinated 
in this region with only 7 out of 54 countries having national HPV vaccination 
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programmes (Bruni et al., 2016, Chido-Amajuoyi et al., 2019). Therefore, there is a 
need to develop cost-effective alternative HPV vaccines, for use particularly in 
developing countries. 
In previous studies, plant-made HPV 16 VLP-based vaccine candidates have been 
shown to induce neutralizing antibodies against type-specific HPVs (Chabeda et al., 
2019, Fernández‐San Millán et al., 2008, Maclean et al., 2007). Furthermore, it was 
shown that CRPV challenged rabbits were protected against experimentally induced 
papillomas, after vaccination with TMV encompassing L2 epitopes  (Palmer et al., 
2006), and CRPV L1 protein (Kohl et al., 2006). These data suggest that plants have 
the potential to produce effective papillomavirus vaccines. 
Neutralizing antibodies are considered the main immune mechanism of  protective 
responses against HPV infections (Pinto et al., 2018, Kemp et al., 2011). Therefore, 
HPV vaccine candidates should be able to elicit neutralizing antibodies. The 
development of PsVs have allowed researchers to measure the neutralization of HPV 
infectivity both in vivo and in vitro. PsVs are currently produced by transfecting 
HEK293TT cells with codon optimized HPV L1 and L2 genes, and a reporter gene 
(SEAP).  These cells are known to over-express simian virus 40 (SV40) large T 
antigen, which enable reporter plasmid replication, and eventually increased PsVs 
production (Buck et al., 2005a). Subsequently, PsVs are used in HPV PBNAs (Buck 
et al., 2005a), which are considered as standard assessment for the immunogenicity 
of HPV vaccines candidates (Lamprecht et al., 2016).  
The usage of PsVs in neutralization assays is based on the ability of PsVs to deliver 
plasmid DNA into cell lines and tissues as an innate virion would (Rossi et al., 2000). 
However, producing PsVs in mammalian cells is a highly expensive system which 
ultimately might be a major drawback in the production of cheaper HPV vaccines for 
use in developing countries. Our group was the first to make PsVs in plants as a cost-
effective alternative. Plant-produced HPV 16 PsVs had comparable results in PBNAs 
to PsVs produced in mammalian cells, a proof concept that plants are a promising 
cost-effective system for the production of PsVs (Lamprecht et al., 2016).  
Efforts toward the production of affordable HPV vaccines in plants mainly focused on 
the oncogenic HPV 16, which has been shown to elicit strong immune response an 
animal model. To date, the antigenicity of plant-produced VLP-based vaccine of other 
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high-risk HPV types has not been evaluated. The production of cost-effective HPV 
vaccines for use in resource-poor regions, particularly Africa was of the main interest 
in this study. This chapter assessed whether plant-produced VLPs of high-risk HPV 
35, 52 and 58 induced humoral immune response as effectively as yeast produced 
VLPs (Gardasil®). Furthermore, the chapter fits in with another greater aim of the 
project, which is to obtain spleens from hyper-immunized (a prolonged immune-
response induction) mice, to produce a mouse anti-HPVs antibody library. However, 
this study just went as far as hyper-immunizing mice and testing the immune response.  
In conclusion, mice were hyper-immunized with Gardasil® and pooled plant-produced 
VLPs of HPV 35, 52 and 58. The immunogenicity of the VLP-based vaccine 
candidates was evaluated by detecting type-specific L1s in ELISAs and western blots 
using sera from immunized mice. Sera from immunized mice were also tested for type-
specific anti-L1 neutralizing antibodies using PBNAs. Furthermore, sera from mice 
hyper-immunized with plant-produced VLPs were tested for the ability to cross-













3.2 Materials and methods 
3.2.1 Mice studies 
This immunogenicity study was approved by the Animal Research Ethics Committee 
at the Faculty of Health Sciences at the University of Cape Town (UCT, AEC 018-
024).  The BALB/c mice used in this study were bred at the UCT Animal Research 
Unit, all handling and procedures done on the animals were done by a registered and 
experienced animal technologist, Rodney Lucas at the Animal Research Unit. Fifteen 
8-week-old female mice were randomly divided into 3 groups of 5 each and housed in 
the biosafety level II (BSL-2) animal laboratory.  Mice were hyper-immunized with 
Gardasil® (positive control), plant-made VLPs or purified empty vector (prepared in 
chapter 2) (Table 3.1). The plant-made vaccine candidates and empty vector negative 
control were emulsified in mineral oil MONTANIDE™ ISA 50 V2 adjuvant at a 60:40 
(vaccine: adjuvant) ratio. MONTANIDE ISA  50 V2 is a ready-to-use oily vaccine 
adjuvant that has previously been used in mice (Cangussu et al., 2018, De 
Vleeschauwer et al., 2018).  
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Mice were acclimatised in the BSL-2 laboratory for 7 days prior to any experimental 
procedures. Three days prior to the first immunization (day 0), pre-bleeds were 
collected from individual mice. Bleed samples were collected from the tail artery using 
a 25G needle. Mice were subcutaneously injected with 50μl into both the left and the 
right flank on day 3, 17, 31 and 45 (every 2 weeks), before obtaining test bleeds on 
day 56.  An additional boost inoculation was administered on day 59, before obtaining 
final bleeds and spleens on day 73. Here, mice were euthanised by exsanguination 
under general anaesthesia. A combination of ketamine/xylazine (200µL per 20g 
mouse) was administered via intraperitoneal injection using a 25G needle. After the 
depth of anaesthesia was confirmed by pedal reflex, mice were placed in dorsal 
recumbency, and a 25G needle was inserted adjacent the xiphoid cartilage and into 
the heart. A maximum of 1.8mL of blood was then collected and stored at 4°C. Mice 
were hyper immunized in order to obtain high affinity binders to HPVs, which was one 
of the goals of this project. Blood was collected in capillary blood collection tubes 
(Impromini®) and serum isolated by centrifugation at 10 000 x g for 10 minutes and 
stored at -20°C. Additionally, spleens from hyper-immunized mice were preserved in 
RNAlater (Thermo Fisher Scientific) at 4°C for overnight to stabilize and protect RNA, 
before stored at -80°C. 
3.2.2 Detection of anti-L1 antibodies in mice sera 
3.2.2.1 Pre-absorption of mice sera 
Purified plant-produced HPV L1 proteins (made in chapter 2) were used as antigens 
in both western blots and ELISAs. It has previously been reported that host cell 
proteins (in this case co-purified plant proteins) will also result in the production of 
antibodies against these proteins that are present in the plant-made vaccine 
candidates (Chabeda et al., 2019, Pineo et al., 2013). This was confirmed by initial 
ELISAs carried out on test and final bleeds which showed high background detection 
of plant proteins in the empty vector serum. Furthermore, the detection of plant-made 
L1 using final bleeds of plant-produced VLPs and empty vector resulted in the 
detection of non-specific bands with high band intensities on western blots. 
To reduce the cross-reactivity of the antibodies present in the sera with host cell 
proteins the final bleeds from mice immunized with plant-made L1 and plant-purified 
empty vector were pre-absorbed using The “Lunchbox” Immunoabsorbent Technique 
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(Rybicki 1990, 2000:  
http://www.mcb.uct.ac.za/mcb/resources/molbio_techniques/lunchbox) (Rybicki et al., 
1990), to potentially remove/reduce antibodies against native plant proteins present in 
the mice sera. Briefly, 6g of un-infiltrated plant leaves were homogenised in 2x HSPBS 
(pH 7.4) using mortar and pestle. The crude extract was filtered through 4 layers of 
22-24μm pore MiraclothTM (MilliporeSigma) to remove plant debris. Nitrocellulose 
membrane was incubated with the crude plant extract at 37°C for 1 hour with agitation. 
The membrane was washed 4x with blocking buffer (5% long life fat-free milk, 1x Tris-
Cl [pH7.5]) before incubation in 1:200 diluted mice serum overnight at 4°C. The 
following day, the pre-absorbed sera were removed and used in all ELISAs and 
western blots analysis in this study. 
3.2.2.2 ELISAs and western blots analysis 
For ELISAs, 96-well plates (Thermo Fisher Scientific) were coated with antigens 
diluted to 80ng/100µl in coating buffer (10Mm Tris pH 8.5) before incubation overnight 
at 4°C with agitation. Plates were blocked with 300μl blocking buffer (5% long life fat-
free milk, 1x Tris-Cl pH7.5) for 1 hour at 37°C, before they were washed 4x with 1x 
TST (0.05% tween 20, 1xTris-Cl pH7.5). Mice sera or rabbit-raised anti-Gardasil® 
antibody at the desired dilution were added to the wells and the plates incubated for 1 
hour at 37°C. The plates were washed as described above and 100µl of 1:5000 
alkaline phosphatase-conjugated anti-mouse IgG secondary antibody (Sigma-
Aldrich®) added to each well and the plate incubated for 1 hour at 37°C. Plates were 
washed 4x with (1x Tris-Cl pH 9.0) after which 200μl SIGMAFAST™ p-nitrophenyl 
phosphate (Sigma-Aldrich®) substrate was added to each well. The plates were 
incubated in the dark for 30 minutes before reading the absorbance using Bio-Tek 
Powerwave XS spectrophotometer at 405nm.  
Controls included: wells coated with coating buffer (to obtain background readings), 
pre-bleeds (negative controls) and rabbit-raised anti-Gardasil® antibody (positive 
control). Plant-produced empty vector was used as negative control for plant-made 
vaccine candidates only.  
ELISA data were all normalised by subtracting the background readings and titres are 
stated as the reciprocal of the maximum dilution with higher absorbance readings than 
the equivalent pre-bleed serum. Moreover, for plant serum, titres with absorbance 
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readings that were higher than the empty vector at the lowest dilution (1:200) were 
considered anti-L1 positive. ELISA experiments were repeated 3 times, and a 
representative of the 3 experiments for each HPV type is reported here.  
Western blots were performed as described in Chapter 2, Section 2.2.9. Pooled mice 
sera were used as primary antibody at a dilution of 1:1000, alkaline phosphatase-
conjugated anti-mouse IgG antibody (Sigma-Aldrich®) diluted at 1:5000 was used as 
a secondary antibody. Pre-bleeds were used as negative control serum, with an 
additional empty vector control for plant-made vaccine candidates. Rabbit-raised 
Gardasil® antiserum (1:2000) was used as positive antibody control and was detected 
with secondary alkaline phosphatase-conjugated anti-rabbit IgG secondary antibody 
(Sigma-Aldrich®) (1:5000). 
3.2.2.3 Statistical analysis 
Quantitative ELISA data were assessed using a two-tailed t-test for experimental and 
control groups. Furthermore, One-way analysis of variance (ANOVA) test was 
performed to assess the difference among HPV types. Significance threshold (p value) 
of 5% (p = 0.05) was used (Charan and Kantharia, 2013). 
3.2.3 Detection of anti-L1 neutralizing antibodies (NAb) in mice sera 
3.2.3.1 HPV PsVs production in HEK293TT cells 
HPV 6, 31, 45, 52 and 58 PsVs were kindly donated by our lab (made by Megan 
Hendrikse and Cathy Pineo), while HPV 16, 18 and 35 PsVs were made in this study. 
Recombinant E. coli harbouring the HPV plasmids (p16 shell, p18 shell, and pshell 35) 
containing both L1 and L2, and pYSEAP (reporter gene plasmid) were obtained from 
Dr John Schiller (National Cancer Institute). HPV and pYSEAP clones were selected 
on media containing ampicillin (100µg/ml) and blasticidin (75μg/ml). Plasmid DNA was 
extracted using endotoxin free PureYieldTM plasmid Maxiprep kit (Promega) and 
stored at -20 °C until transfection of HEK cells. 
3.2.3.2 HEK293TT cells culturing and transfection 
PsVs were made as described in the pseudovirus production protocol of the 
Laboratory of Cellular Oncology 
https://home.ccr.cancer.gov/lco/pseudovirusproduction.htm (Buck et al., 2005b). Cells 
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were cultured in 1x complete Dulbecco’s Modified Eagle Medium (cDMEM) and 1x 
GlutaMAXTM-I (Gibco). The medium was supplemented with 10% fetal bovine serum, 
1% non-essential amino acids, and 250μg/ml Hygromycin B (Roche). Cells were 
cultured in pyrogen-free Corning cell culture flasks and unless otherwise stated, 
incubated in a 37°C, 5% CO2 incubator. 
For transfection, cells that reached 60-70% confluency, were transfected by mixing 
37.5µg of HPV plasmid DNA and 37.5µg of pYSEAP DNA into 3ml of serum-free 
DMEM medium. A volume of 100μl X-tremeGENE HP DNA transfection reagent 
(Roche) was added and the medium incubated at room temperature for 15 minutes. 
The transfection mixture was then added onto cells and incubated for 40-48 hours. 
3.2.3.3 Collection, maturation and purification of PsVs 
Approximately 40-48 hours post-transfection, cells were harvested by centrifugation 
for 2 minutes at 832 x g using 221.08 V01 rotor (Beckman). Briefly, culture medium 
was removed and added into a sterile conical tube and centrifuged as described 
above.  After centrifugation the supernatant was discarded. Cells attached to the flasks 
were removed by adding 0,005% trypsin-EDTA (Gibco) and incubated for 
approximately 5 minutes at 37°C. The enzyme reaction was deactivated by adding 
cDMEM medium, and the resuspension added to the pellet obtained after 
centrifugation of the media.  Cells were collected by centrifugation as above. The 
supernatant was aspirated and discarded, and the pellet washed with 0.5mL 
Dulbecco’s phosphate buffered saline (DPBS) (Invitrogen), centrifuged and the 
supernatant discarded. 
For maturation of PsVs, the pellet was partially resuspended in DPBS and transferred 
into a 2ml siliconized-microcentrifuge tube. DPBS was removed by centrifugation, the 
pellet volume was estimated, and the pellet was resuspended in 1.5 volumes of DPBS-
9.5mM MgCl2; 1/20th volume of 10% triton X-100; 1/40th of 1M ammonium sulphate 
(pH 9.0) and 1/1000th of RNase (Ambion). The resuspension was gently mixed by 
tapping the microcentrifuge tube and incubated at 37°C overnight. 
The following day, the matured PsVs were purified. Briefly, the microcentrifuge tube 
with cell resuspension containing matured PsVs was incubated on ice for 5 minutes, 
before centrifugation using a Benchtop centrifuge (Thermo Fisher Scientific) at 5000 
x g for 5 minutes. The supernatant was collected in a fresh siliconized tube and pellet 
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washed in 2x volume DPBS and centrifuged again. The supernatant was added to the 
first supernatant collected and the washing step was repeated twice more, using one-
pellet volume for both the first and second wash, with the second wash step 
supplemented with 0.8M NaCl. Supernatants collected from all the washing steps were 
combined and centrifuged again before purification by ultracentrifugation. For 
purification, the supernatant was loaded into OptiprepTM discontinuous gradients (1ml 
27%, 1ml 33% and 1ml 39%) and centrifuged for 4.5 hours at 234 843 x g, 15°C using 
a SW 55 Ti rotor (Beckman). After centrifugation 250µl factions were collected from 
the bottom of the tubes by puncturing the lowermost part of the tube. 
3.2.3.4 Analysis of HPV PsVs 
Fraction 4 -12, where PsVs were expected to sediment were analysed on dot blots 
using conformational type-specific monoclonal antibodies (MAbs) from Dr Neil 
Christensen (Penn State Cancer Institute) at a dilution of 1:1000 (Table 3.2) and anti-
mouse IgG alkaline phosphatase-conjugated secondary antibody (Sigma-Aldrich®) at 
1:5000. Dot blots were performed as described in Chapter 2, Section 2.2.11.1.  





Successful encapsidation of the secreted alkaline phosphatase reporter plasmid by 
PsVs was assessed by incubating PsVs (1:100) with HEK293TT cells for ~72 hours 
and SEAP signal determined. Briefly, cells that reached 60-70% confluency were 
collected by adding 0,005% trypsin for 5 minutes, before neutralizing with complete 
medium. Cells were collected by centrifugation for 2 minutes at 832 x g using 221.08 
V01 rotor (Beckman) and resuspended in fresh medium, after which they were diluted 
to 3 x 105 cells/ml. Cells were then seeded (100µl/well) in pyrogen-free 96-wells tissue 
culture plates (Sigma-Aldrich®) and left to attach by incubating the plates for at least 4 
hours. The outer wells were unused to avoid evaporation and were filled with medium. 
HPV type MAbs 
HPV 16 H16V5 
HPV 18 H18.J4 
HPV  35 H35Q8 
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A volume of 100µl/well of PsVs were added onto cells in duplicate (due to the high 
cost of the SEAP kit). 
Controls included: cells only (to obtain background readings) and cells transfected with 
pYSEAP plasmid (SEAP positive control). Plates were incubated for 72 hours, after 
which SEAP were signals detected.  
SEAP signals were determined using a Great Escape kit 2.0 (Clontech Laboratories, 
Inc) according to the manufacturer’s instructs, with a few adjustments. The volume 
used in the assays in this study were 0.6 volumes that of the recommended volumes 
in the neutralization assay manual of the Laboratory of Cellular Oncology. Briefly, 15µl 
of infected cells were transferred into corresponding wells of a white 96-well plate 
(Thermo Fisher Scientific) and 45µl 1x dilution buffer was added. The plate was 
covered and incubated at 65°C for 30 minutes, after which the plate was chilled on ice 
for 5 minutes before adding 60µl SEAP substrate. The plate was incubated at room 
temperature for 45 minutes before SEAP signal determined using GloMax®-Multi 
Detection System (Promega). 
PsVs fractions with the highest SEAP signals and amount of L1 (based on the dot 
blots) were pooled and analysed under TEM (as described in Chapter 2) for the 
presence of PsVs. PsVs were stored at -80°C until further analysis. 
3.2.3.5 Pseudovirion-based neutralization assays 
3.2.3.5.1 Optimization of PsVs and Neutralization antibodies dilutions 
PsVs were initially tested at different dilutions to determine the dilution at which to use 
them in neutralization assays. Briefly, cells were grown until they were 60-70% 
confluent and diluted to 3 x 105 cells/ml. Cells were then seeded (100µl/well) in 
pyrogen-free 96-wells tissue culture plates (Sigma-Aldrich®) and left to attach by 
incubating the plates for about 4 hours. A dilution range of 1:250-1:1000 of PsVs were 
prepared in sterile conical tubes using complete DMEM medium. PsVs dilutions were 
added onto cells (100µl/well) in duplicate. Cells only were used to get background 
readings and 100µl medium was added to these wells. Plates were incubated for 72 
hours in the incubator before analysing SEAP signals as described in Section 3.2.3.4. 
Data were normalised by subtracting the cells only data, and the minimum dilution that 
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gave a robust SEAP signal (at least a reading of 2 million relative light unit (RLU) was 
selected to be used in the assays.  
Furthermore, known type-specific NAbs were tested to determine the dilution that 
completely neutralized PsVs. Here, the dilution of PsVs that was chosen to be used in 
PBNAs was prepared for each HPV type. NAbs working stocks were then prepared in 
fresh DMEM medium before they were added directly to the PsVs to dilute to the 
desired dilutions (Table 3.3). The dilution ranges were selected based on previous 
titrations done by our group. Antibodies were left to attach to PsVs for at least 1 hour 
at 4°C before adding onto cells. Controls included: cells only (background readings) 
and PsVs only (no neutralization).  
Plates were incubated for 72 hours before analysing SEAP signals as described in 
Section 3.2.3.4. Data were normalised by subtracting cells only readings. PsVs only 
data were then set as maximum (100%) SEAP signal and the dilution that reduced 
SEAP signal by ~100% when compared to PsVs only control was selected to be used 
in PBNAs. 
 Table 3.3: Type-specific neutralizing antibodies used in PBNAs  
NAb Name HPV type Dilution range Fold increase 
H16V5 HPV 16 5x103-2x104 2 
H18.J4 HPV 18 1x104 and 
2x104- 2x106 
2 and 10 
H35Q8 HPV 35 5x102- 5x105 10 
 
3.2.3.5.2 Neutralization assays 
L1-neutralization assays were done as described in the Laboratory of Cellular 
Oncology files 
https://ccrod.cancer.gov/confluence/display/LCOTF/NeutralizationAssay (Buck et al., 
2005b). Briefly, cells were grown as above until they reached 60-70% confluency and 
diluted to 3 x 105 cells/ml. Tissue culture plates were seeded with 100µl/wells and 
incubated for 4 hours. PsVs, type-specific NAbs and mice sera working stocks were 
each diluted in fresh medium. Pooled mice sera and NAbs were added directly onto 
PsVs to reach desired dilutions. PsVs with serum or NAbs were incubated for 1 hour 
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before being added onto cells and incubated for 72 hours. SEAP signals were detected 
as described in Section 3.2.3.4. 
Controls included were: Cells only (background readings); PsVs only (no 
neutralization); PsVs pre-incubated with known NAbs (positive neutralizing antibody 
control); PsVs pre-incubated with empty vector serum (negative neutralizing antibody 
control for plant serum). 
Empty vector serum was used at a one-point dilution (lowest dilution).  All raw data 
were normalised for background by subtracting the cells only data, thereafter PsVs 
only data were set as the maximum (100%) SEAP signal. For each HPV type, 
neutralization is expressed towards its own PsVs only control, and data plotted as 
percentage relative light unit (% RLU). The assays were repeated 3 times, and a 
representative assay for all the 3 experiments of each type is reported here. 
3.2.3.6 Statistical analysis 
One-way ANOVA test was performed to assess the difference in neutralization ability 
among HPV types, with a significance threshold (p value) of 5% (p = 0.05) (Charan 














3.3  Results  
3.3.1 Detection of anti-L1 antibodies in mice sera 
3.3.1.1 ELISA analysis 
To determine whether plant-produced HPV VLPs can elicit a humoral immune 
response in mice as efficiently as the commercially available Gardasil®, mice were 
hyper-immunized with a total of 6µg of plant-produced VLPs or 1/5th of human dose of 
Gardasil® (total amount of 24µg). The humoral immune response was analysed by 
testing type specific anti-L1 antibodies in ELISA using plant-produced VLPs as 
antigen. 
The first step was to determine if there were any non-responders to the vaccine 
candidates. Sera from individual mice inoculated with plant-made VLPs and Gardasil® 
were tested against HPV 58 and HPV 16 antigens, respectively. These HPV types 
were chosen from each group to avoid wasting sera by testing individual mice on each 
antigen. Serum from mice inoculated with empty vector, served as a negative control 
to which serum against plant-produced VLPs could be compared, these sera were 
tested against HPV 58 only. All sera were tested at 1:200 dilution and successfully 
detected corresponding L1 proteins (results not shown). Sera from individual mouse 
in each group were then pooled for further analysis.  
Pooled sera were titrated using each of the HPV types included in the vaccine 
candidates to determine the anti-L1 endpoint titres. Sera were titrated using a 4-fold 
serial dilution ranging from 1:200-1:51200 dilution. Serum collected from mice 
vaccinated with Gardasil® was only tested on HPV 6, 16 and 18 VLPs as we do not 
have the HPV 11 L1 gene with which to produce HPV 11 VLPs, therefore it was 
excluded in this study. The empty vector serum and serum obtained from plant-made 
VLP-vaccinated mice were tested against all 3 HPV types (HPV 35, 52 and 58) 
included in the plant-made vaccine candidate. Pre-bleed sera served as negative 
control against the corresponding HPV types and were tested at the lowest dilution 
(1:200). Rabbit-raised anti-Gardasil® antibody (1:5000) served as a positive control 
that confirmed the presence of antigens in the coated samples and validated the 
experiments. Anti-L1 titres are stated as the reciprocal of the maximum dilution with 




The commercial Gardasil® vaccine elicited a significant immune response, with the 
highest anti-L1 titre of 51200 observed for all three antigens tested (Figure 3.1A). It is 
also important to note that, Gardasil® serum detected HPV 16 L1 better when 
compared to HPV 6 and 18. This was expected, as Gardasil® contained more HPV 16 
L1 (8µg) compared to HPV 6 and 18 (4µg) per dose (1/5th human dose was used). 
However, regardless of the different amounts of L1 VLPs in the vaccine dose, no 
statistically significant difference was observed in the immune response elicited 
against these HPV types (p=0.8351). As expected, no anti-L1 response observed in 
the pre-bleed serum from mice inoculated with Gardasil® which served as a negative 
control (Figure 3.1B). Rabbit-raised anti-Gardasil® successfully detected all HPV VLPs 





Figure 3.1: Indirect ELISA detection of anti-L1 in Gardasil® serum using plant-
made L1 coating antigens: A) Four-fold serial dilution of pooled Gardasil® serum B) 
Absorbance values obtained for pre-bleeds at 1:200 dilution C) Rabbit-raised anti-
Gardasil® positive control at 1:5000. Markers and error bars indicate mean values and 
standard deviation from triplicate readings. 
Serum from mice immunized with plant-produced VLPs 
High background signals were obtained for the negative control empty vector serum 
and serum from mice immunized with plant-produced VLPs, these results were 
consistent with the ELISA results from the test bleeds at day 56 of vaccination (results 
not shown). Higher absorbance readings observed possibly resulted from antibodies 
raised against co-purified host cell proteins, which have been reported before 
(Chabeda et al., 2019, Pineo et al., 2013). Pooled sera were pre-absorbed against 
plant proteins at a dilution of 1:200, to potentially remove antibodies against host cell 
proteins. Pre-absorption of sera successfully removed most antibodies against plant 
contaminants. This was evident by the decrease in absorbance values obtained for 
ELISAs, especially for the negative control group after pre-absorption. The highest 
absorbance values before pre-absorption were ~1 and 3 for the empty vector and 
plant-produced VLPs serum, respectively. After pre-absorption, these values dropped 
to ~0,5 and 2, indicating successful reduction of antibodies against native plant 
proteins (Figure 3.2A). 
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Plant-produced L1 VLPs elicited a significant humoral immune response against type-
specific HPVs (Figure 3.2A). The highest anti-L1 titres of 12800 was observed against 
all the 3 HPVs (Figure 3.2A). The immune response elicited against HPV 35, 52 and 
58 were comparable to each other and the difference in immune response observed 
between these HPV types was not statistically significant (p= 0.9900). Titres of 200-
3200 were observed for the empty vector, which may have been due to antibodies 
against plant contaminants (Figure 3.2A). This suggested that pre-absorption did not 
remove all the antibodies against host cell proteins. The immune response against 
HPV 35, 52 and 58 were statistically significant when compared to the empty vector 
control (p=0,0372; p=0,0443 p=0.0371, respectively). As expected, pre-bleeds 
negative controls from mice inoculated with VLPs and empty vector showed no anti-
L1 titres for all three HPV types (Figure 3.2B). The positive control rabbit-raised anti-
Gardasil® antibody successfully detected all HPV types, which validated these 





Figure 3.2: Indirect ELISA detection of anti-L1 in plant serum using plant-made 
L1 coating antigens: A) Four-fold serial dilution of pooled plant serum B) Absorbance 
values obtained for pre-bleeds at 1:200 dilution C) Rabbit-raised anti-Gardasil® 
positive control at 1:5000 dilution. Labels: EV= empty vector. Markers and error bars 
indicate mean values and standard deviation from triplicate readings. 
3.3.1.2 Western blot analysis 
After successfully detected anti-L1 antibodies in ELISAs, the ability of sera from 
immunized mice to detect denatured L1 proteins was assessed by western blot 
analysis using plant-made antigens and mammalian-made antigens (in the case of 
sera from mice immunized with plant-made VLPs). Pooled final bleeds and pre-bleed 
sera of all vaccine groups were analysed for corresponding type-specific anti-L1 
immune responses. Rabbit-raised anti-Gardasil® antibody obtained from our lab was 
used a positive antibody control. 
Gardasil® serum 
Gardasil® serum successfully detected type-specific HPV L1 proteins at ~56 kDa and 
is validated by the positive anti-Gardasil® antibody control which detected the same 
bands (yellow arrows, Figure 3.3A and B). As expected, no L1 proteins were detected 




Figure 3.3: Anti-L1 western blot analysis with Gardasil® serum: A) Final bleeds B) 
Rabbit-raised anti-Gardasil® positive control C) Pre-bleeds. Labels: M= pre-stained 
protein standard (kDa).  L1 proteins (~56 kDa, yellow arrow) were detected with either 
final bleeds, pre-bleeds (1:1000) or anti-Gardasil® (1:2000) and anti-mouse or anti-
rabbit IgG alkaline phosphatase-conjugated secondary antibodies (1:5000). 
 Serum from mice immunized with plant-produced VLPs 
Initially western blots were carried out using sera that was not pre-absorbed with host 
cell proteins. Plant-produced VLPs serum successfully detected type-specific HPV L1 
at ~56 kDa (yellow arrow), with no L1 band observed in the empty vector serum (Figure 
3.4A and B, respectively). However, high background was obtained when probing 
plant-produced VLPs with non-pre-absorbed serum from this study, as evidenced by 
the detection of smears and non-specific bands (~82 and 32 kDa) with high intensity 
on western blots, especially in the empty vector control sample (green arrows, Figure 
3.4B). This possibly resulted from antibodies raised against co-purified host cell 
proteins. Therefore, western blots were further performed using pre-absorbed sera. 
Pre-absorbed plant serum successfully detected type-specific HPV L1 proteins at ~56 
kDa (yellow arrow, Figure 3.4A). As expected, no L1 proteins were detected by pre-
absorbed empty vector serum (Figure 3.4B).  
By comparing the blots detected using pre-absorbed serum with those detected with 
serum that was not pre-absorbed, it was evident that pre-absorption of sera 
sucessfully removed most of the antibodies against host proteins. Non-specific binding 
was still obtained with the pre-absorbed sera, however the intensity of background 
signal and bands detected was much lower compared to non-pre-absorbed sera 
(Figure 3.4A and B), indicating the successful removal of most of the host-cell-specific 
antibodies. These results are consistent with those observed in ELISA experiments, 
where a decrease in absorbance values was observed after using pre-absorbed 
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serum. The low background observed when using pre-absorbed plant-produced VLPs 
and empty vector sera further suggested that pre-absorption did not remove all the 
antibodies against host cell proteins.  
Since pre-absorption of sera did not remove all the antibodies against host cell 
proteins, serum from mice inoculated with plant-made VLPs was futher tested to see 
whether they will detect mammalian-made L1 in type-specific PsVs used in this study. 
Mammalian-made L1s were detected using non-pre-absorbed serum. As expected the 
serum successfully detected HPV L1 proteins at ~56 kDa (yellow arrows) with no no-
specific bands and/or background signal observed (Figure 3.4C). Furthermore, a band 
at ~46 kDa (black arrow) was observed for HPV 52 L1, this might have been a product 
of protein cleavage, which possibly happened during storage (Figure 3.4C). The ability 
of plant serum to successfully detect mammalian-made L1s with non-specific binding 
demostrated the novelty of anti-serum obtained in this study. This confirmed that the 
background signals detected when using plant-made antigens are against plant 
contaminants that were present in vaccine samples.  
The positive control, rabbit-raised anti-Gardasil® antibody, successfully detected L1 
proteins at ~56 kDa (yellow arrow, Figure 3.4D). This validated the western blot 
experiments. As expected, no L1 proteins or background were observed in the pre-
bleed negative controls of both VLPs and empty vector vaccinated groups (Figure 3.4E 
and F). This further confirmed that the background signals detected in western blots 





Figure 3.4: Anti-L1 western blot analysis with serum from plant-produced VLPs: 
A) Plant-made antigens with non-pre-absorbed and pre-absorbed VLPs sera and 
empty vector sera (B); C) Mammalian-made antigens with non-pre-absorbed VLPs 
serum; D) Rabbit-raised Gardasil® anti-serum; E and F) VLPs and empty vector pre-
bleeds, respectively. Labels: M= pre-stained protein standard (kDa).  L1 proteins (~56 
kDa, yellow arrows) were detected with either VLPs final bleeds, empty vector final 
bleeds and pre-bleeds serum (1:1000) or anti-Gardasil® (1:2000) and anti-mouse or 
anti-rabbit IgG alkaline phosphatase-conjugated secondary antibodies at 1:5000.  
3.3.1.3 Overview of type-specific anti-L1 titres of mice sera 
Mice were hyper-immunized with Gardasil® and plant-produced fully assembled VLPs 
with aggregates and capsomeres (Chapter 2, Figure 2.6, Section 2.3.4). Purified 
empty vector was used as a negative control for plant-produced vaccine candidate. 
Hyper-immunization of mice resulted in a strong humoral immune response, 
suggesting the presence of L1 epitopes on the surface of L1 particles. Table 3.4 










Table 3.4: Anti-L1 immune response in mice sera 
HPV types Vaccine group Anti-L1 titre Detection of 
denatured L1 
6 Gardasil® 51200 Y 
16 Gardasil® 51200 Y 










35 Empty vector None N 
52 Empty vector None N 
58 Empty vector None N 
Y= Yes; N=No 
3.3.2 Detection of anti-L1 neutralizing antibodies in mice sera 
After successfully confirming that plant-produced VLPs and Gardasil® induced type-
specific humoral immune responses in mice. The next step was to analyse whether 
the elicited antibodies can neutralize HPV PsVs in PBNAs and ultimately potentially 
prevent HPV infections. This was achieved by detecting anti-L1 neutralizing antibodies 
using PBNAs. Even though the study focused on cost-effective alternatives for HPV 
vaccine production, mammalian-made PsVs were used in PBNAs instead of the 
alternative cost-effective plant-produced PsVs. This is because of the non-specific 
binding to antibodies against plant contaminants observed in ELISAs and western 
blots experiments (Section 3.3.1.1 and 3.3.1.2, respectively), which I thought might 
negatively influence PBNAs results for plant-produced VLPs serum.  
3.3.2.1 Dot blots analysis of purified PsVs  
HPV PsVs made in this study were expressed in HEK293TT cells and purified by 
OptiprepTM discontinuous density gradient ultracentrifugation. Fractions 4-12 were 
analysed by detecting L1 proteins with type-specific MAbs on dot blots (Table 3.2, 
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Section 3.2.3.4). L1 was detected mostly across all the fractions, with strong detection 
in less dense fractions (F9-12), corresponding to 27% OptiprepTM, for HPV 16 (Figure 
3.5A). Whereas HPV 18 and 35 L1s were strongly detected in more dense OptiprepTM 
fractions (F4-8), which corresponds to 33-39% OptiprepTM (Figure 3.5B-C).  
It is important to note that, some particles may not contain a reporter plasmid therefore 
VLPs may be formed instead of PsVs. Fully assembled PsVs encapsidating the 
reporter plasmid usually sediment in a less dense  OptiprepTM fraction as compared to 
empty particles (Buck et al., 2005a). Therefore, data observed on the dot blots might 
suggest that HPV 16 made fully encapsidated PsVs as compared to HPV 18 and 35 
where L1s were detected in more dense OptiprepTM fractions.  
 
Figure 3.5: Dot blot analysis of purified PsVs: A) HPV 16 PsVs B) HPV 18 PsVs C) 
HPV 35 PsVs. L1 proteins were detected with type-specific monoclonal antibodies 
(1:1000) and anti-mouse IgG alkaline phosphatase-conjugated secondary antibodies 
(1:5000).  
To confirm if L1 and L2 assembled into particles with a reporter plasmid.  L1-positive 
fractions were further analysed for SEAP signal at a dilution of 1:100. Fractions 
showed diverse SEAP signals with better SEAP signals observed for HPV 16 PsVs 
(results not shown). This further suggested that HPV 16 PsVs encapsidated the 
reporter plasmid (SEAP) better than those of HPV 18 and 35, which probably had a 
mix population of VLPs and PsVs. Fractions with the highest SEAP signals and most 
intense L1 spots observed on dot blots were pooled for TEM and PBNAs analysis. 
3.3.2.2 Transmission electron microscopy analysis of purified PsVs 
The morphology of purified PsVs was analysed using TEM (Figure 3.6).  Fully 
assembly PsVs (40-60nm) were observed for all HPV types (white arrows, Figure 3.6). 
HPV 16 showed low yield of fully assembled particles, with small PsVs (35-39nm) 
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(blue arrow, Figure 3.6A) also observed.  Whereas HPV 18 and HPV 45 were entirely 
populated by fully assembled particles (white arrows, Figure 3.6B and C). It not 
surprising that small PsVs were observed for HPV 16, as this might have partially 
contributed to strong detection of L1 in less dense OptiprepTM fractions (Figure 3.5). 
 
Figure 3.6: TEM micrographs of purified mammalian-produced PsVs: Samples 
were extracted from HEK293TT cells and purified using discontinuous OptiprepTM 
gradients and viewed under TEM at the magnification of 40 000 X. Bars are 100nm in 
size. Labels: white arrows- full assembled PsVs; blue arrows- small PsVs and/or 
capsomeres.  
3.3.2.3 Pseudovirions and neutralization antibodies dilutions selected for 
PBNAs  
Pooled PsVs were initially tested to determine the minimum dilution that gave robust 
SEAP signals (at least 2x106 RLU readings), which is the dilution used in PBNAs. 
PsVs were tested using 2-fold dilution ranging from 1:250-1:1000 and based on the 
SEAP signal, a dilution was selected for each type (red dots, Figure 3.7). For HPV 16 
strong SEAP signals were observed at 1:250-1:1000, therefore PsVs were used at 
1:1000. On the other hand, HPV 18 and 35 gave robust signal at 1:250-1:500 and 
PsVs were used at 1:500.  
HPV 16 gave better SEAP signal than HPV 18 and 35 (Figure 3.7). This is in consistent 
with the results obtained from analysing individual PsVs fractions at a dilution of 1:100 
(results not shown). This further suggested that HPV 16 PsVs encapsidated the 



















Figure 3.7: Selection of HPV PsVs dilution: PsVs were tested using 3 dilutions, to 
determine the minimum dilution of each HPV to be used in PBNAs. Error bars indicate 
standard deviation between duplicate readings. 
Type-specific neutralizing antibodies by Christensen et al. (1996a) were used as 
positive controls and were tested at different dilutions (Table 3.3, Section 3.2.3.5.1), 
to achieve ~100% reduction of SEAP signals. All antibodies neutralized their 
corresponding HPV types and a suitable dilution was used as a control for each type 
(Table 3.5). HPV 6, 31, 45 and 52 PsVs were all used at 1:100 while HPV 58 PsVs 
were used at 1:500, meanwhile their corresponding NAbs were used at 1:20000 for 
H6.C6 and H31A6 (HPV 6 and 31, respectively), 1:100 for H52D11 and H45N5 (HPV 
52 and 45, respectively) and 1:20 000 for H58J6.3 (HPV 58) (Megan Hendrikse, 
personal communication). 
Table 3.5:  Dilutions of positive neutralizing antibodies used in PBNAs  
NAbs Name HPV type Dilution used in 
PBNAs 
% neutralization 
H16V5 HPV 16 1:5000 100 
H18.J4 HPV 18 1:10000 95 
H35Q8 HPV 35 1:500 99 
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3.3.2.4 Pseudovirion-based neutralization assays 
Anti-L1 neutralizing antibodies were detected using PBNAs with NAbs as a positive 
control. Sera that resulted in 50% reduction of SEAP signals when compared to a 
PsVs only control were considered neutralizing positive and were further titrated to 
determine the endpoint of neutralizing titres. Plant-produced empty vector serum was 
used as a negative control for serum from mice immunized with plant-produced VLPs.  
Negative control serum was tested at the lowest dilution (1:4000) only. 
Pooled sera were initially tested at 1:50 dilution to determine if there were any anti-L1 
neutralization antibodies. All sera reduced type-specific SEAP signals by 100% 
(completely neutralizing) at 1:50 dilution (data not shown) and were further titrated. 
Sera were initially titrated using a 4-fold serial dilution ranging from 1:50-1:51200, 
however PsVs were completely neutralized up to a dilution of 1:12800 and endpoint 
titres could not be established from these data (data not shown). Based on these data, 
sera were re-titrated using a 4-fold serial dilution ranging from 1:4000 to 1:1024000. 
Gardasil® serum 
The Gardasil® vaccine has already been studied and shown to elicit homologous and 
heterologous neutralizing antibodies (Smith et al., 2007a, Einstein et al., 2009). 
Therefore, due to the high cost of the SEAP assay the neutralization ability of Gardasil® 
serum was only tested on HPV 16 and 18 PsVs in this study. Serum successfully 
neutralized both HPV 16 and HPV 18 PsVs, the cut off of anti-L1 neutralizing titres 
was a 50% reduction of SEAP signal (red-dashed line, Figure 3.8A). Serum 
neutralized PsVs at 4000-16000 titres by ~97%. The highest neutralization titre 
observed was 64000, which neutralized HPV 16 PsVs (˂50% SEAP signal observed) 
but not HPV 18 PsVs (>50% SEAP signal detected) (Figure 3.8A). Suggesting that, 
the serum had more potent neutralizing antibodies for HPV 16 compared to HPV 18. 
This was not surprising as the vaccine contained a higher concentration of HPV 16 L1 
than HPV 18 L1. However, no statistically significant difference in the neutralization 
ability between HPV 16 PsVs and HPV 18 PsVs, p > 0.05 (p = 0.3191), was observed. 
The positive neutralizing antibody controls successfully neutralized their 




Figure 3.8: HPV 16 and 18 neutralization assays: A) Gardasil® serum B) PsVs and 
positive control antibodies (H16V5 for HPV 16 and H18.J3 for HPV 18). Markers and 
error bars indicate mean values and standard deviation from duplicate readings. 
 Serum from mice immunized with plant-produced VLPs 
For plant-produced VLP serum, ~95% neutralization was observed at 1000-16000 
titres for all the type-specific PsVs. Furthermore, ~91% neutralization was observed at 
titres of 64000 for all HPV types (Figure 3.9A). The highest neutralization titre of 
256000 was observed for HPV 35 and 52 PsVs, 50% cut off (red-dashed line, Figure 
3.9A). This indicated that serum from mice inoculated with plant-made VLPs had more 
potent neutralizing antibodies for HPV 35, followed by HPV 52 then HPV 58. However, 
there was no statistically significant difference in the neutralization ability between 
these types (p=0.1436). Empty vector sera did not neutralize any of the HPV PsVs, 
and the reduction in SEAP signal observed for HPV 35 and 52, might have been due 
to large variation between duplicate readings (3.9B). The ability of positive neutralizing 
antibody controls to successfully neutralize their corresponding PsVs, showed the 
validity of the neutralization assays (Figure 3.9B). 
To my knowledge, there is no data on evidence of cross protection of heterologous 
HPVs by HPV 35, 52 or 58. Therefore, plant-produced VLPs sera, were tested against 
all the heterologous PsVs that were available in our lab (HPV 6, 16, 18, 31, and 45), 
to see whether they will neutralize any of them. However, plant-produced serum did 
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not neutralize any of heterologous PsVs tested in this study at 1:50 dilution of the sera 
(results not shown).  
 
Figure 3.9: HPV 35, 52 and 58 neutralization assays: A) Plant VLPs serum B) PsVs; 
empty vector (EV) and positive control antibodies (H35Q8 for HPV 35 and H52D11 for 
HPV 52 and H58J6.3 for HPV 58). Markers and error bars indicate mean values and 
standard deviation from triplicate readings. 
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3.3.2.5 Overview of type-specific neutralizing anti-L1 titres of mice sera 
Table 3.6 shows a summary of the neutralization ability of Gardasil® and plant-
produced VLP sera obtained from immunized mice. Overall, all sera had type-specific 
neutralizing titres which successfully reduced homologous SEAP signals when 
compared to their corresponding PsVs only control. However, plant serum did not 























Table 3.6: Neutralizing anti-L1 titres elicited by Gardasil and plant-derived VLPs. 











16 Gardasil® Y 16000 ˃64000 
























N - - 
35 Empty 
vector 
N - - 
52 Empty 
vector 
N - - 
58 Empty 
vector 
N - - 
Y= Yes; N= No; - = None 
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3.4 Discussion  
3.4.1 Anti-L1 antibodies in mice sera 
HPV VLPs are generally known to have comparable antigenicity characteristics to 
native virions. This is because of their repetitive surface-displayed epitopes, ability to 
activate B-cells and particulate nature, especially their size 40-60nm (Fifis et al., 2004). 
Their size seems to be ideal for nanoparticles uptake by dendritic cells (Aljabali et al., 
2018, Fifis et al., 2004). In this study, the humoral immune response of Gardasil® and 
plant-made HPV L1 VLPs was assessed in mice to determine if plant-produced VLPs 
are suitable to make HPV vaccines.  
Gardasil® is known to elicit humoral anti-L1 antibodies against high-risk HPV 16 and 
18 (2 main oncogenic HPVs that are responsible for 70% of all cervical cancers) and 
low-risk HPV 6 and 11 (mainly responsible for genital warts) (Handisurya et al., 2010, 
Joura et al., 2008). Interestingly, Gardasil® has been shown to offer additional 
protection against HPV 31 (closely related to HPV 16) (Brown et al., 2009a). Here, 
Gardasil® induced type-specific significant immune responses with the highest 
antibody titre of 51200 observed for all HPV tested (Figure 3.1B). Titres obtained in 
this study are similar to titres obtained elsewhere, where sera from Gardasil® 
immunized immune-competent individuals showed 6400-102400 titres in ELISAs 
(Handisurya et al., 2010).  
Plant-produced L1 VLPs elicited type-specific anti-L1 immune responses, and no anti-
L1 was detected in the empty vector serum in ELISAs (Figure 3.2). However, high 
absorbance readings were obtained when plant-produced antigens were detected with 
empty vector and plant-produced VLPs sera, suggesting that the serum contained 
antibodies against co-purified host cell proteins (results not shown). This was not 
unusual for the purification method used in this study and had been reported on before 
(Chabeda et al., 2019). Furthermore, heparin chromatography purification of plant-
produced L1:L2 chimeras or yeast-produced L1 also resulted in host cell proteins co-
purification (Pineo et al., 2013, Kim et al., 2010). The commercially available HPV 
vaccines are expensive partially due to their purification procedures (Chen and Lai, 
2013). Therefore, co-purification of host proteins is not unique to plants, and need to 
be addressed. Here, pre-absorption of serum against crude plant extract from non-
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infiltrated plants resulted in the removal of plant antibodies, which was evidenced by 
decreased absorbance readings (Figure 3.2).   
Plant-produced L1 antigens have been reported to induce type-specific humoral 
immune responses (Chabeda et al., 2019, Fernández‐San Millán et al., 2008, Maclean 
et al., 2007, Biemelt et al., 2003, Varsani et al., 2003, Warzecha et al., 2003). The 
highest anti-L1 titre observed in serum from mice inoculated with 6µg of plant-
produced L1 in this study was 12800 for all HPV included in the vaccine (Figure 3.2B). 
Chabeda et al. (2019)  reported titres of 6400 after immunizing mice with 5µg of plant-
produced HPV 16 L1 VLPs. The higher titre (12800) observed in the current study 
suggested the presence of more intact VLPs with better displayed epitopes, therefore 
better uptake by dendritic cells. Furthermore, mice in this study were hyper-immunized 
which might have further contributed to the higher titre observed. Plant-made HPV 16 
L1 have been reported to induce higher titres than those reported in this study, titres- 
20000, 51200 and 40960 (Pineo et al., 2013, Fernández‐San Millán et al., 2008, 
Maclean et al., 2007). High anti-L1 titres in these studies might be associated with the 
amount of L1 VLPs (10-30µg) used to immunize mice.   
Western blots showed the detection of type-specific HPV L1 proteins at ~56 kDa with 
Gardasil® and plant-produced VLPs sera, with no L1 bands observed in the pre-bleeds 
and empty vector control in case of plant serum (Figure 3.3 and 3.4). Western blots 
experiments were validated by the detection of the same bands by the positive rabbit-
raised Gardasil® serum (Figure 3.3B and Figure 3.4D). However, non-specific bands 
at ~82 and 32 kDa with high background signals were observed in westerns detected 
with non-pre-absorbed serum, especially in the empty vector (Figure 3.4B). These 
results are  consistent with results previously reported in our lab. Chabeda et al. (2019) 
observed background signals when detecting plant-made HPV 16 antigens on western 
blots with sera from mice vaccinated with plant-made HPV 16 L1 and L1/L2 chimaera 
VLPs. Furthermore, Pineo et al. (2013) reported non-specific bands at ~80 kDa after 
detection of E. coli made HPV 16 L2 antigens with sera from mice inoculated with plant 
extract. These illustrated the presence of host cell contaminants in the vaccine 
samples, further demonstrating the need to explore purification methods for HPV VLPs 
to achieve pure vaccine samples. In this study, antibodies against host cell proteins 
were reduced by pre-absorbing sera against plant proteins. Background signals were 
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low after using pre-absorbed sera, suggesting the specificity of anti-L1 antibodies after 
pre-absorption of the sera.   
Non-pre-absorbed plant-produced VLPs serum were further analysed for their ability 
to detect type-specific mammalian-made L1 and to assess whether any background 
signal will be observed. As expected the serum successfully detected HPV L1 proteins 
at ~56 kDa with no non-specific bands and/or background observed (Figure 3.4C). 
This suggested that the background signals observed was specific for plant 
contaminants. 
3.4.2 Neutralization assays 
Potential prophylactic HPV vaccine candidates should be able to elicit neutralizing 
antibodies (Rybicki, 2010). Therefore, in this study, neutralization ability of anti-L1 from 
mice serum was analysed using PBNAs- the gold standard assessment of the efficacy 
of HPV vaccine candidates (Lamprecht et al., 2016). 
As described in Section 3.3.2, PsVs used in this study were expressed in mammalian 
cells due to interference with plant-made antigens observed in ELISAs and western 
blots (Section 3.3.1.1 and 3.3.1.2). However, mammalian expression system is 
expensive and might hinder the development of affordable HPV vaccines. Plant-
produced HPV 16 PsVs are feasible and  have been tested by our group (Lamprecht 
et al., 2016). Testing sera on plant-made PsVs in PBNAs would have been a good 
idea, as it will reduce the cost associated with the production of HPV vaccines and 
needs to be explored. However, it was beyond the scope of this study to make all the 
PsVs tested in both plant and mammalian cells. Therefore, for the purpose of this 
study, mammalian-made PsVs were used in PBNAs, as no background signals were 
observed after the detection of mammalian-made L1 on western blot (Figure 3.4E).  
Gardasil® serum neutralized HPV 16 and 18 PsVs at titres of 4000-64000 (Figure 
3.8A). These titres are in range with the neutralizing titres observed from sera of mice 
immunized with 0.1x human dose (25600- 51200 titres) (Wu et al., 2015). Furthermore, 
titres of 1600-25600 were obtained from humans immunized with Gardasil® 
(Handisurya et al., 2010).  
Serum from mice immunized with plant-produced L1 also elicited type-specific 
neutralizing antibodies. Neutralization was observed at 4000-64000 titres for HPV 58, 
84 
 
and 4000-256 000 titres for HPV 35 and 52 (Figure 3.9A). L1 neutralization titres 
observed in this study were ~40-fold higher than titres reported in other studies- using 
plant-produced HPV 16 VLPs against type-specific PsVs: 6400 (Chabeda et al., 2019, 
Maclean et al., 2007); 50-500 (Pineo et al., 2013) and  400 (Fernández‐San Millán et 
al., 2008). However, mice were hyper-immunized in this study, which might explain 
the high titres observed here. The ability of sera to prevent cell infection by PsVs have 
been associated with defence against experimental and natural infections (Breitburd 
et al., 1995). Therefore, plant-derived HPV VLPs have the potential to be used as 
prophylactic vaccine, which might alleviate cervical cancer and related diseases in 
resource-poor countries. 
No neutralization activity was observed against heterologous HPV 6, 16, 18, 31, and 
45 PsVs in this study. This however, was not surprising as there is no data on the 
evidence of cross-protection between these HPV types. Mice were immunized with 
the total L1 dose that was made up of VLPs with aggregates/capsomeres, and not 
with a homogenous population of VLPs. Therefore, there is a probability that the L1 
neutralizing epitopes for the aggregates/capsomeres were not sufficiently displayed to 
create neutralizing antibodies against heterologous PsVs or these HPV types just do 
not cross-neutralize.  
I cannot directly compare the immune response of plant-produced VLPs to that of 
Gardasil® for different reasons. Firstly, these VLPs were produced in different 
expression systems and have different adjuvants, and secondly different doses were 
used in this study. Gardasil® was used at 1/5th human dose (24µg) while plant-
produced VLPs were used at 6µg. However, plant-produced VLPs induced humoral 
immune response effectively as the commercially available HPV Gardasil® vaccine. 
This was evidenced by the type-specific anti-L1 neutralizing titres observed (Figure 
3.9), suggesting that plant-produced VLPs are suitable for making HPV vaccines. 
In conclusion, hyper-immunizing mice with Gardasil and pooled plant-produced VLPs 
of HPV 35, 52 and 58 successfully induced type-specific humoral immune response 
with neutralizing antibodies. This work has successfully demonstrated that plant-made 
HPV VLPs are highly and appropriately immunogenic, demonstrating the potential to 
use plant-based transient expression systems to produce cost-effective HPV VLP-
base vaccines, particularly for developing countries. 
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4 Chapter 4: Conclusions and future work. 
 
Commercially available HPV vaccines are effective at preventing HPV infections. 
However, these vaccines are expensive, which is preventing their use in developing 
countries, where ~85% of cervical cancer deaths occur (Ferlay et al., 2018). 
Consequently, there is a need to develop affordable HPV vaccines, which was of 
specific interest here. Plants have been utilised as a cost-effective alternative to 
conventionally used expression systems. Therefore, the aim of this study was to 
evaluate the plant-based transient expression system as a tool to develop cost-
effective multivalent prophylactic HPV vaccines that can potentially be used in low-
and-middle income countries. The highest burden of cervical cancer is reported in 
Africa (Zhai and Tumban, 2016), therefore high-risk HPV types that are relevant in an 
Africa context were of main interest in this study.  
Human-codon optimized L1 of the 8 most common oncogenic HPV types in Africa 
(HPV 16, 18, 31, 33, 35, 45, 52 and 58) and 2 low risk HPV types (HPV 6 and 11) 
were transiently expressed in N. bethamiana using the pTRACTP plant expression 
vector, which targets proteins to the chloroplast. All 10 types were successfully 
expressed in plants and assembled into VLPs, with capsomeres and aggregates also 
observed in the same fractions.  
Purification of VLPs by sucrose and Optiprep™ density gradient ultracentrifugation 
resulted into co-purification of host cell proteins in this study. Therefore, research 
focusing on improving the purity of plant-produced HPV VLPs, without compromising 
the yield and structural integrity of these VLPs need to be established. Several 
chromatography strategies such as heparin, cation-exchange and size exclusion have 
been explored for the purification of HPV VLPs, however host cell proteins were 
evident (Pineo et al., 2013, Kim et al., 2010). Additionally, purification of HPV VLPs by 
these methods is time consuming and may result in significant L1 losses and/or 
degradation (Park et al., 2008). Commercially available HPV vaccines are made by in 
vitro disassembly/reassembly of purified L1 to get homologous population of VLPs 
(Zhao et al., 2014). Therefore, optimizing disassembly/reassembly of plant-produced 
VLPs might overcome the presence of host cell proteins in the vaccines, and ultimately 




In this study, mice were hyper-immunized with Gardasil® and plant-made VLPs. 
Gardasil® elicited a strong humoral immune response against the tested HPV 6, 16 
and 18 antigens. HPV 11 could not be tested, as we do not have the HPV 11 L1 gene 
that can be expressed in plants to make L1 proteins.  It is reported in literature that, 
Gardasil® can induce neutralizing antibodies against homologous (HPV 6, 11, 16 and 
18) and heterologous (HPV 31) types. Therefore, for the purpose of this study, the 
neutralization ability of sera from mice immunized with Gardasil® was only tested on 
the 2 main oncogenes HPV 16 and 18. As expected, sera successfully neutralized 
HPV 16 and 18 PsVs.  
Plant-produced VLPs selected for mice studies also elicited strong humoral immune 
responses with type-specific neutralizing antibodies. However, sera from mice 
immunized with plant-produced VLPs did not neutralize any of the heterologous HPV 
(-6, 16, 18, 31, and 45) PsVs tested, these results were not surprising as to my 
knowledge there is no data on evidence of cross-protection of tested heterologous 
types by HPV 35, 52 and 58. Mice were immunized with a mixture of VLPs, 
capsomeres and aggregates, and there is a possibility that the L1 neutralizing epitopes 
were not sufficiently displayed on the surface of capsomeres and aggregates to create 
neutralizing antibodies against heterologous PsVs or these HPV types do not cross-
neutralize. In summary, in vitro disassembly/reassembly of plant-produced L1 to make 
homogenous preparations of VLPs should be investigated to improve the homogeneity 
of the vaccine preparation, this could potentially improve neutralizing antibody titres 
obtained after vaccination with the plant-made VLPs.  
This study successfully demonstrated that plant-produced VLPs are highly 
immunogenic and are potentially suitable for making multivalent prophylactic HPV 
vaccines, especially for developing countries. This can be achieved by expressing 
different HPV types in plants, and ultimately pool them to make a single vaccine that 
helps protect against multiple HPV types like Gardasil9®. Multivalent vaccines help 
reduce the number of injections required as it covers multiple serotypes in one 
vaccine. 
Previous research in our lab has successfully made HPV 16 PsVs in plants with 
comparable results to PsVs produced by mammalian cells  (Lamprecht et al., 2016). 
It would be therefore interesting to evaluate sera from mice vaccinated with plant-
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made VLPs using plant-made PsVs to compare with the neutralization results obtained 
in this study. This will assess whether antibodies against native plant proteins had any 
effect on the neutralization assays performed in this study. 
This study fits in with a broader aim that would be to produce anti-HPV single chain 
fragment variable (scFvs) antibodies from the spleens obtained from the hyper-
immunized mice. Spleens obtained from this study will be used to create an HPV 
antibody library using the phage library approach. The library will be screened for 
binders (scFv) to HPV antigens after which the scFV sequences will be cloned into 
plant expression vectors to produce these HPV antibodies in plants. These anti-HPV 
antibodies can be used either in research or as diagnostic reagents, as there are no 
commercially available anti-HPV antibodies and diagnostic kits. CamVir is the only 
commercially available monoclonal antibody for detection of HPV 16. However, it 
cannot be used to detect other HPV types. Expression of antibodies in plants is a well-
established method (for review see Yusibov et al. (2016)) and producing feasible anti-
HPV antibodies in plants will allow their usage not only in developed countries but, 
also in developing countries. 
In conclusion, this study successfully demonstrated that plant-produced VLPs can 
elicit strong humoral immune responses in mice, demonstrating the ability to use plant 
transient-expression system to develop affordable yet effective multivalent HPV 
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